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ABSTRACT

The focus of this work is structural and functional studies of wild-type and
active-site mutants o f human adenosine deaminase. Two active-site amino acids,
Glu217 and H is238, were previously substituted w ith alanine by site-directed
mutagenesis. The Glu217Ala and His238Ala mutants showed little or no changes in
Zn content and Km value, yet dramatic loss o f enzym e activity. Circular dichroism
studies o f the solution conformation o f w ild-type and mutant human adenosine
deaminases indicate that 30 to 50% of a-helical structure is lost in Glu217Ala and
His238Ala, respectively, whereas (3-sheet structure is fully retained.

Inhibitor

binding is measured by a fluorescent assay. Dissociation constants for transitionstate analog inhibitors are similar for wild-type and mutant enzymes, suggesting that
inhibitor and substrate binding determinants are preserved in the mutants. Protein
stability studies show that Glu217Ala and His238Ala are less stable to thermal, urea,
and guanidinium chloride denaturation than w ild-type.

Because the enzym e

conform ational changes caused by substitution o f Glu217 and His238 mainly
destabilizes the protein with only minor effects on substrate and inhibitor binding,
the loss of enzyme activity is probably due to the modification o f functional groups
that are critical for catalysis.

The active-site Zn environm ent o f w ild-type,

Glu217Ala, and His238Ala mutant adenosine deam inases is probed by EXAFS.
There are five

ligands coordinated to Zn in the free enzyme and ground- and

transition-state analog inhibitor complexes of these three adenosine deaminases,
suggesting the presence o f a water/hydroxide o r a hydroxyl group.

Zn-ligand

distances o f the mutants are similar to those o f the wild-type, indicating that the
active-site of mutants are intact upon substitution. W ild-type and His238Ala form a
transition state with the transition-state analog inhibitor purine riboside whereas with

ix
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Glu217Ala a ground state is formed. The findings are consistent with the proposed
catalytic mechanism based on the X-ray crystal structure o f mouse adenosine
deaminase, and provide further insight into the effects o f these active site residues on
the structure, stability and function o f human adenosine deaminase.
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CHAPTER 1: INTRODUCTION

Adenosine Deaminase Background
Adenosine deaminase (ADA, adenosine aminohydrolase, EC 3.5.4.4) is a
purine salvage pathway enzyme that catalyzes the irreversible deam ination o f
adenosine and deoxyadenosine to inosine and deoxyinosine, respectively.

The

enzym e has been isolated as a soluble single polypeptide from erythrocytes
(M.W .=36,000) (Van der W eyden & Kelly, 1976), and from leukemic cells and
thymus (M.W.=41,000) (Wiginton et al., 1981). Adenosine deaminase is present on
the cell surface, as well as in the cytoplasm o f all cells, such as human fibroblasts,
rabbit renal tubular cells, and human mononuclear blood cells (Van der W eyden &
Kelly, 1976; Andy & Komfeld, 1982; Schrader et al., 1988; Aran et al., 1991), with
high enzyme activity present in lymphoid tissue (Carson et al., 1977) and highest
activity present in the gastrointestinal tract (W itte et al., 1991).

The human

adenosine deaminase protein is encoded by a single gene on the long arm o f
chromosome 20 (Tischfield et al., 1974) that has 12 exons separated by 11 introns
and spans about 32,000 base pairs (bp) o f DNA (Wiginton et al., 1986). In lung and
kidney, adenosine deaminase has also been associated with a ADA binding protein
and appeared as a dimeric membrane-bound "complexing protein" (M.W.=298,000)
(Schrader & Stacy, 1969; Daddona & Kelley, 1970; Daddona & Kelly, 1979) . At
first the function of the association was not ascertained (Schrader et al., 1990). More
recent studies are focused on two sets o f proteins: CD26, a 110-kD glycoprotein
playing an integral role in T cell activation; and p43, a 43 kD protein which can be
recognized by antibody to CD26. The results suggest that two peptides derived from
p43 are completely identical to those o f residues 35-64 and 172-206 of the human

1
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adenosine deaminase, and CD26 is identical to adenosine deaminase binding protein of
the dimeric "complexing protein" (Kameokaet al., 1993).
Adenosine deaminase has a central role in the maintenance of immune function
and competency.

In humans, an absence or deficiency o f functional adenosine

deaminase catalytic activity is associated w ith severe immunodeficiency and
lymphopenia in both T- and B-cell lineages (Giblett et al., 1972; Coleman et al.,
1978).

An inherited deficiency o f adenosine deam inase activity accounts for

one-fourth o f all severe combined immunodeficiency disease (SCID), which is a rare
human hereditary disorder characterized by the absence of mature T and B
lymphocytes, in children (Dissing & Knudsen, 1972; Parkman et al., 1975; M artin &
Gelfand, 1981). These effects are believed to be mediated by the build-up o f
deoxyadenosine in mostly lymphoid cells as well as urine, plasma, bone marrow cells,
and erythrocytes (Mills et al., 1976) which is converted to the ultimate toxic metabolite
deoxyadenosine triphosphate (dATP) (Dissing & Knudsen, 1972; Parkman et al.,
1975; Chen et al., 1978; Cohen et al., 1978a; Cohen et al., 1978b; Coleman et al.,
1978; Donofrio et al., 1978; Fox & Kelley, 1978; M artin & Gelfand, 1981). DeoxyATP formation is increased in incubated erythrocytes (Agarwal et al., 1976) and
lymphocytes (Raivio et al., 1977), and dATP concentration in lymphocytes is ten
times greater than the normal value (Polmar et al., 1976). It is unclear why lymphoid
tissue (specifically immature T-cells) has a higher associated enzyme activity o f
deoxyadenosine phosphorylating enzymes (Carson et al., 1977) generating higher
levels of the toxic dATP metabolite (Donofrio et al., 1978) than other tissues. It is
also unclear why lymphoid cells are especially sensitive to high levels o f this dATP
metabolite (Coleman et al., 1985), although the potent inhibition o f dATP to the
enzyme ribonucleotide dephosphate reductase (Thelander & Reichard, 1979) and the
rate limiting step in DNA synthesis would likely affect the extensive cell turnover seen
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in this lineage (Carson et al., 1977). Other lineages turn over rapidly also, and it may
be then that the expression o f terminal transferase in lymphoid cells in combination
with increased ATP levels is actually generating the lethal effect.
In principle, the adenosine deaminase deficiency disease could be treated by
supplying a source o f active adenosine deaminase, which will bring down the levels of
toxic metabolites allowing lym phocyte differentiation to proceed (Vega, 1992).
Various therapeutic strategies have been utilized to solve the fatal (by 1-2 years o f age)
[Pollara, 1979 #18] deficiency o f adenosine deaminase enzyme activity. Bone marrow
transplantation from allogeneic donors results in the repopulation o f the blood cells of
the ADA' infants and the correction o f the deficiency, however, only one-third o f all
patients have a matched donor (Parkman et al., 1975; Kantoff et al., 1988). Treatment
has also been effective by normal red-cell transfusions of ADA+ erythrocytes (Polmar
et al., 1976) although the promising outcome o f overcoming the deficiency has been
short-lived in many infants.

Injection o f polyethylene glycol-m odified bovine

adenosine deaminase (PEG-ADA) has also been administered (Hershfield et al., 1987)
and promising results have been obtained since much more PEG-ADA can be given
than in red-cell transfusions. Therefore, the blood activity levels are increased and
potent transfusion side effects including iron build-up and risks of viral infection are
reduced in PEG-ADA treatment. In the late eighties, adenosine deaminase deficiency
SCID was also selected as the first target for human gene therapy replacem ent
protocols using modified retroviral vectors containing the ADA-cDNA (Kantoff et al.,
1986; Anderson, 1990; Culver et al., 1991). In this approach, the A D A ' SCID patient
is reimplanted with autologous T lymphocytes which have received an active copy of
the ADA-gene by retroviral vector-m ediated gene transfer and have thereby been
converted into ADA+ cells. The activity o f the retrotransfected ADA' gene product is
expected to restore the immuno-competence o f the recipient (Ferrari et al., 1991). The
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experiment constitutes the first gene therapy trial on humans (Culliton, 1990). Clinical
trials o f augmentation therapy using this technique are underway. The m ost recent
approach is a gene correction therapy (Vega, 1992). Among other desirable common
properties for gene therapy, gene correction principally keeps the original expression
properties of the corrected gene and avoids the introduction o f foreign (retroviral or
others) sequences into the genome o f human being(Vega, 1991).
The overproduction o f adenosine deaminase, which causes a 45-70 fold
increase o f erythrocyte adenosine deaminase activity in humans, has been observed in
kindred with severe hereditary hemolytic anemia's (Valentine et al., 1977). Patients
with this dominantly inherited entity have a mild anemia and decrease of erythrocyte
adenosine nucleotides to less than 50% o f that o f comparable reticulocyte-rich blood.
The increased adenosine deaminase activity is also associated with some leukemias
(Coleman & Hutton, 1975). Potent inhibitors of adenosine deaminase have been used
alone or in com bination with other drugs as antimetabolic, antineoplastic, and
antibiotic agents to treat certain leukemias in humans (Fox & Kelley, 1978; Coleman,
1983).

The underlying m echanism for overexpression o f the gene and its

consequences are unknown.
Furtherm ore, since adenosine deaminase is a key enzyme in adenosine
metabolism, it also affects cellular levels o f adenosine. Many biological properties of
adenosine are identified: (1) It is toxic to mammalian and bacterial cells; (2) Its
presence is associated with inhibition of the immune response, coronary vasodilation,
delayed neurotransm ission, inhibition or stimulation o f hormone secretion, and
changes in the m etabolism o f a num ber o f tissues such as lipolysis, and
glycogenolysis. Adenosine also has many biochemical effects including: direct
activation of adenylate cyclase, inhibition o f pyrimidine biosynthesis, and diminution
of phosphoribosyl-pyrophosphate (PP-ribose-P) synthesis (Robio et al., 1969;
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Bumstock, 1972; Chagoya de Sanchez et al., 1974; Fain & W ieser, 1975; Fox &
Kelley, 1978).
In addition to its deaminating activity, adenosine deaminase also catalyzes the
hydrolysis of several 6-substituted purine derivatives including a number of clinically
important antimetabolites (Zielke & Suelter, 1971). At least 80 compounds are known
to bind to adenosine deaminase, some as substrates but most as inhibitors that show
different types o f inhibition (W ilson & Quiocho, 1993). Some of these inhibitor
compounds have been instrumental in postulating a reaction mechanism for adenosine
deaminase. Phosphorylated nucleosides are not substrates or inhibitors for adenosine
deaminase (Zielke & Suelter, 1971). Understanding the catalytic mechanism of
adenosine deaminase is o f special interest because analog inhibitors of adenosine with
chemotherapeutic potential (Agarwal, 1982) as well as drugs directed against other
enzymes are degraded by adenosine deaminase. These drugs could be modified to
have a longer pharm acological half-time if it were understood how adenosine
deaminase interacts with these compounds.
The actual catalytic mechanism employed by adenosine deaminase in the
deamination reaction o f adenosine and deoxyadenosine has been the subject o f much
speculation for more than two decades. Studies using competitive inhibitors, usually
transition and ground-state analogs (Kati & Wolfenden, 1989b), have implicated a
histidine residue o f the protein as hydrogen bonding to the sixth position -OH group of
the hydrated purine intermediate. It is proposed that the deamination reaction actually
proceeds by direct water attack (addition-elimination mechanism) (Kurz & Frieden,
1987) rather than by a double-displacement mechanism (Jones et al., 1989). Indeed,
the importance o f hydrogen bonding to site 6 o f the purine in stabilizing the
rate-determining tetrahedral intermediate (Kurz & Frieden, 1987) is seen in the
observation that K( for the competitive inhibitor of adenosine deaminase containing an

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

6

-OH group at site 6 is lO^-fold lower than that observed for the hydrogen substituted
moiety (Kati & Wolfenden, 1989a) Other potential groups implicated in the reaction
mechanism are carboxyl (Kati & Wolfenden, 1989a) and imidazole moieties (Kurz &
Frieden, 1983).
Time-resolved fluorescence spectroscopy has also been used (Philips et al.,
1987; Philips et al., 1989) to demonstrate that adenosine deaminase undergoes
conformational changes upon binding inhibitors. This also may serve to stabilize the
proposed tetrahedral intermediate and thus increase the catalytic efficiency o f
the enzyme.
The adenosine deaminase catalyzed deamination appears to be encounter
limited (Kurz et al., 1992) with a kcat o f 375 s*1 and a fccat/K m o f 1.4 x 107 M_1 s_I.
The rate enhancement o f approximately 2 x 1012 (Frick et al., 1987) shows this
enzyme to be more efficient than has been described previously (Wolfenden & Kirsch,
1968). Support for the enzyme mechanism proceeding via formation of a tetrahedral
intermediate has come from several studies (W olfenden et al., 1969; Evans &
Wolfenden, 1973; Kurz & Frieden, 1983). l3C NMR studies with purine riboside
showed that hybridization o f C-6 changes from sp2 to sp3 in the binary complex (Kurz
& Frieden, 1987) with the nucleophile at C-6 being either a water molecule or a thiol at
the active site of the enzyme. Subsequent NMR and UV absorption studies (Jones et
al., 1989) gave evidence that the substrate was bound as a 1,6 covalent hydrate.
Further suggestions on residues involved in m echanism s o f adenosine
deaminase catalytic activity have been provided by a comparison o f the amino acid
sequences of the & coli. mouse and human forms of adenosine deaminase (Chang et
al., 1991).

In this study, a comparison was also made w ith eukaryotic AMP

deaminases, which have an analogous function, in order to identify potential catalytic
residues solely on the basis o f functional conservation. Four residues (His214,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

7

Cys262, Asp295 and Asp296) were assigned putative catalytic roles. These residues
are compatible with those suggested from the ground-state and transition-state analog
studies outlined above.
The key to the understanding o f the catalytic m echanism o f adenosine
deaminase came with the publication in 1991 o f the crystal structure (2.4 A resolution)
o f mouse adenosine deaminase complexed to a nearly ideal transition-state analog
inhibitor 6(R )-hydroxyl-l,6-dihydropurine riboside (W ilson et al., 1991). The
adenosine deaminase protein was purified from an overexpressing E\ coli strain
containing a plasmid with the mouse adenosine deaminase sequence and complexed to
purine riboside, the transition state analog inhibitor. Adenosine deaminase was found
to contain 8 central (3 strands and 8 peripheral a-helices in a barrel format. Mouse
adenosine deaminase was also found to complex a previously undetected Zn moiety in
the active site with 4 amino acid residues involved in lending the Zn coordination.
His214 and Asp295 (as identified by (Chang et al., 1991) both appear to be involved
in coordinating the Zn molecule. In fact, Asp295 seems to have a dual role in that it
also acts as a general base in the proposed addition-elimination (with tetrahedral
intermediate) catalytic mechanism (W ilson et al., 1991). Residues at sites Glu217,
glyl84, Asp296 (as identified by Chang et al., 1991) and His238 are proposed to be
directly involved in the catalytic mechanism. This agrees well with the identification of
conserved residues between functionally similar proteins (Chang et al., 1991; Wilson
et al., 1991). The Cys residue at site 262 (as identified by Chang et al., 1991),
however, is believed not to have any functional role in the catalytic mechanism. In
fact, none o f the 5 Cys residues in the polypeptide chain are implicated.
The most recent enzyme catalytic mechanism (Figure 1.1) was proposed based
on the X-ray crystal structures o f mouse adenosine deaminase complexed with a
transition-state analog inhibitor 6(R )-hydroxyl-1,6-dihydropurine riboside and a
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ground-sate analog inhibitor 1-deazaadenosine, in which Zn plays a crucial role by
facilitating formation o f a pre-transition state with a bound activated water molecule or
a hydroxide (Wilson & Quiocho, 1993). In this mechanism, Glu217, which is ideally
located coplanar with the purine ring, donates a proton to N 1 o f substrate adenosine,
thereby reducing the N1-C6 double bond character and rendering C6 susceptible to
nucleophilic attack and transformation from sp2 to sp3 in the tetrahedral adduct.
His238 acts as a general base/acid and plays an important role in enzyme catalysis.
Asp295 remains coordinated to the Zn and is considered to hydrogen bond to the
activated water or hydroxide and optimize the geometry for the hydroxide addition to
the C-6 of adenosine. Thus, the tetrahedral intermediate is formed. Formation rather
than decay of the tetrahedral intermediate is believed to be the most difficult (possibly
rate-limiting) step (Kurz & Frieden, 1987). A Zn-activated water or a hydroxide is
proposed to be the attacking nucleophile according to the mouse ADA/HDPR and
ADA/DAA X-ray crystal structures and the abstracted proton on Ne2 of His238 attacks
the N6 amino leaving group. However, the proton source for the leaving -NH 2 group
is far from certain since this leaving group would be pushed into an essentially
hydrophobic environment; the proton may come from the incipient hydroxyl group,
shuttled by the Asp295 (W ilson & Quiocho, 1994). The precise chirality of the
chemical reaction is dedicated by the favorable geometry together with the location of
the Zn and Asp295 in the B-face side of the purine as hydroxide attack occurs on this
side only. The key point o f the proposed mechanism is the activation o f the water,
which is believed to involve coordination o f the oxygen to the powerful Zn
electrophile, donation o f one hydrogen to a hydrogen bond with 051 o f Asp295, and
donation of the other hydrogen to a hydrogen bond Ne2 o f His238.
Adenosine deaminase was recently reported to bind the reaction product
inosine as its 1,6-hydrate, a gem-diol that appears to be even more closely analogous
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than purine riboside, to highly activated intermediates in substrate deamination (Wilson
& Quiocho, 1994). Indeed, the structure o f the proposed gem -diol would bear an
even closer resemblance to a tetrahedral intermediate in oxygen exchange from water
into inosine, a reaction earlier found to be catalyzed by adenosine deaminase
(W olfenden & Kirsch, 1968). It was also suggested most recently that although
covalent hydrates are formed as high-energy interm ediates during catalysis by
adenosine deaminase, it is unlikely to accumulate at the active site. In contrast with
this actual reaction intermediate, the hydrated form o f purine riboside, in which
hydrogen replaces the leaving group -NH 2 , is able to accumulate at the active site
because its equilibrium of hydration is much less favorable (about 10-7 M) and can be
overcome by forces o f attraction at the active site (Shih & Wolfenden, 1996).
While much is now known about the enzymatic activity of human ADA,
including its interactions with various substrates (Wiginton et al., 1981) and inhibitors
(Kurz & Frieden, 1987; Philips et al., 1987; Philips et al., 1989), no direct
information is available concerning the enzyme active site.
Various natural point mutations o f the am ino acid sequence o f human
adenosine deaminase have been described (Akeson et al., 1989; Medin et al., 1990),
and some functional implications examined (Wilson et al., 1991). The locations of 8
point mutations derived from sequencing complementary DNAs from cell lines derived
from SCID patients are outlined in relation to the structural changes made (Akeson et
al., 1989). All o f these site-specific mutations are in regions o f the protein that will
likely disrupt the folded structure of the enzyme but will not directly affect the catalytic
mechanism. It is expected that active-site mutations, lacking any functional activity,
would be lethal and selected against. Therefore little information can be gained from
the analyses of these existing mutations.
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The demonstration that human recom binant adenosine deaminase can be
overexpressed in and purified from insect larvae (Medin et al., 1990) combined with
techniques for readily introducing site-specific mutations in cDNA has led to an
increased interest in examining the proposed catalytic mechanism o f human adenosine
deaminase. It is now possible to introduce site-specific changes that directly affect
catalysis while the disruption o f the folding o f the enzyme is minimized since the
three-dimensional structure is known. It is also now possible to overproduce these
altered proteins in a system amenable to the production and purification o f variant
enzyme forms for detailed enzyme analyses.
The functional role of amino acid residues in or close to the active site o f
adenosine deaminase has been probed by site-directed mutagenesis o f the human
enzyme based on the X-ray crystal structure of mouse enzyme (Bhaumik et al., 1993).
The human enzyme has 11 additional amino acids at the C-terminus and over 80%
homology with the murine enzyme in the rest o f the sequence. The active site residues
are completely conserved. Replacement o f four amino acid residues in the active site
with alanine: H isl7, His214, Glu217, and His238, caused dramatic loss o f enzyme
activity though the enzyme still had a bound Zn. The His 17Ala and His214Ala
mutants gave low protein yields during purification. However, the Glu217Ala and
His238Ala mutants could be isolated in excellent yield and purity.

Extended X-Ray Absorption Fine structure
Since X-rays have wavelengths on the order o f atomic dimensions, these
highly energetic photons can be used to elucidate the molecular structure o f materials.
One example is X-ray absorption spectroscopy (XAS). A typical X-ray absorption
spectrum is shown in Figure 1.2. At a well-defined X-ray photon energy, a sharp rise
in absorption coefficient is observed. This is called an X-ray absorption edge and is
due to electron dissociation from a core level of one type of atom (the absorbing atom).
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Figure 1.2. An X-ray absorption spectrum plotted as absorption coefficient versus
photon energy. Bottom, full spectrum showing the pre-edge and EXAFS regions.
Top, expanded view o f the edge region (Scott, 1985).
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Above the edge, the quasi-periodic modulations in the X-ray absorption coefficient are
referred to as extended X-ray absorption fine structure (EXAFS). EXAFS refers to
both the quasi-period modulations in the x-ray absorption coefficient above the x-ray
absorption edge and also to the techniques used to analyze them in terms of molecular
structure. The analysis o f EXAFS may lead to direct information about the local
environment around the absorbing atom.

The EXAFS technique yields radial

structural information within a 4-5 A radius around the absorbing atom. Specifically,
the question to be answered by EXAFS is: "How many o f what type o f atom are at
what distance from the absorbing atom?" Since EXAFS only gives radial distance
information, orientation o f the absorbing atom sites within a sample is not important.
Amorphous samples (e.g., powders, solutions, frozen solutions, gases) are amenable
to study by this technique.
The X-ray absorption spectrum o f a given sample will exhibit an edge at a
photon energy equal to the ionization potential o f a bound electron in the constituent
atoms o f the sample. Scanning the photon energy causes every atom in the sample to
give rise to several absorption edges, which are named for the shells o f the Bohr atom
(K, L, M, etc.) as the photon energy matches the ionization potential o f each bound
electron as illustrated in Figure 1.3.
In the quasi-periodic modulations in the EXAFS region, the X-ray photons
absorbed have a higher energy than that necessary to ionize the absorbing atom.
Defining the X-ray absorption edge energy as Eo (the threshold energy) and assuming
a photon energy o f E (E>Eo), the extra energy E-Eo is transferred into kinetic energy
o f the photoelectron, which is also a photoelectron wave. The kinetic energy of the
photoelectron changes throughout the EXAFS region by energy scanning o f the
incident X-ray radiation.

In a condensed media, such as liquids or solids, an

absorbing atom is surrounded by neighboring atoms called scattering atoms.
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Figure 1.3. Schematic diagram relating the X-ray absorption spectrum to the atomic
energy level diagram. X-ray photon absorption is indicated by the arrows in the
energy level diagram, each giving rise to an absorption edge in the top spectrum.
Some Lin and K X-ray absorption edge energies are tabulated below the diagram
(Scott, 1985).
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Considering the simplest possible arrangement o f atoms, a diatomic molecule with an
absorbing atom a and a scattering atom s is shown in figure 1.4. The photoelectron
wave propagating from a and scattering from s are shown in solid and dashed arcs,
respectively.

Figure 1.4a shows that, for energy E j, the amplitude o f the

backscattered photoelectron wave at the absorbing atom a is a maximum with the
dashed arc through a, thus giving rise to a maximum in the modulation o f XAS as
shown in Figure 1.4c. Increasing the photon energy to E 2 generates a photoelectron
with a shorter wavelength (larger energy), the scattering o f which is illustrated in
Figure 1.4b. At E 2 , the backscattered photoelectron has a minimum amplitude at atom
a, generating a minimum in XAS as shown in Figure 1.4c. It is demonstrated that the
EXAFS region is a periodic modulation o f X-ray absorption as the photoelectron
wavelength is scanned and the backscattered photoelectron wave periodically goes in
and out o f phase with the outgoing photoelectron wave (an interference effect). Since
EXAFS modulation depends on the nature and location o f the scattering atom s, proper
analysis o f EXAFS can elucidate the local structure around the absorbing atom a as
following: The neighboring atoms of absorbing atom a contribute a series o f damped
sine waves to the overall EXAFS spectrum o f a , which can be described by three
measurable quantities - frequency, amplitude, and phase. The frequency o f the sine
wave is a measure o f the distance between a and scattering atoms, the amplitude of the
sine wave is a measure of the number of a certain type o f scattering atoms at that
distance, and both the amplitude and the phase of the sine wave help define the identity
of scattering atoms around the absorbing atom a. In a word, as mentioned before,
EXAFS can determine how many of what type o f atoms at what distance from the
absorbing atom a.
Besides the single-scattering theory of EXAFS discussed above, there is also
the multiple-scattering phenomenon for EXAFS that the photoelectron encounter two
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Figure 1.4. Diagram of photoelectron waves generated by X-ray absorption at two
different energies, (a) and (b) indicate the photoelectron scattering for energies E[ and
E 2 , respectively, as indicated in the spectrum in (c). In (a), the scattered photoelectron
has a maximum am plitude at the absorbing atom a and in (b), the scattered
photoelectron has a minimum amplitude at atom a. This leads to a maximum and
minimum, respectively, in the EXAFS shown in (c) (Scott, 1985).
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Figure 1.5. One possible multiple-scattering pathway for a photoelectron generated by
X-ray absorption by atom a in the presence of two scattering atoms S[ and S2 - The
scattering pathway indicated is a
The multiple-scattering contribution to the
EXAFS depends on the distances involved and on the angles 0i and 02 (Scott, 1985).
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or more scattering atoms in its "round trip" back to the absorbing atom a (Figure 1.5).
When atoms (including the X-ray absorbing atom a and its neighbor) are arranged in a
linear or near collinear fashion, such as CN- or CO- in imidazole or carboxyl, the
forward scattering will be strongly enhanced and EXAFS contributions from
neighboring atoms as far as 8 A can be observed (Teo, 1981). The single-scattering
theory of EXAFS is not applicable in these situations and multiple-scattering processes
involving the intervening atoms should be taken into account in order to provide
accurate structural characterization o f the scattering atoms around the absorbing metal
atom a.
Zn plays a crucial role in the proposed catalytic mechanism o f adenosine
deaminase. However, information concerning Zn environment has been rather limited
so far. Because of its filled 3d-shell, Zn molecule is not accessible by spectroscopic
techniques such as optical absorption, NMR, and EPR. Although Zn sites in proteins
may be studies indirectly by spectroscopy, such as Cd substitution and monitoring by
113Cd NMR spectroscopy or Co substitution and monitoring by UV-visible or CD,
these surrogates may not be faithful reporters o f Zn sites. XAS in general, and
EXAFS in particular, offer a unique and direct probe o f Zn centers in proteins. In the
work o f this dissertation, EXAFS is successfully used to monitor the structural
changes of ligands coordinated to the active-site Zn in free wild-type, Glu217Ala and
His238Ala mutant human adenosine deaminases and their ground- and transition-state
analog inhibitor complexes.
This dissertation is based on two manuscripts individually submitted to
Biochemistry.
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CHAPTER 2: SPECTROSCOPIC STUDIES OF ACTIVE SITE MUTANTS
OF HUMAN ADENOSINE DEAMINASE

Introduction
Adenosine deaminase (EC 3.5.4.4) is an important enzym e in the purine
salvage pathway which catalyzes the irreversible hydrolytic deam ination o f
adenosine or deoxyadenosine to their respective inosine product and ammonia.
Adenosine deaminase is present at varying levels in the cytoplasm o f virtually all
animal tissues and microorganisms. Because it plays a central role in maintaining
immune competence and function, adenosine deaminase has become a focus o f
interest for structure-function studies o f the molecular basis o f genetic disease.
Adenosine deaminase has been isolated as a soluble single polypeptide of
different electrophoretic m obilities and molecular weights from erythrocytes,
leukemic cells, and thymus (Van der Weyden & Kelly, 1976; Carson et al., 1977;
W iginton et al., 1981). In humans, adenosine deaminase exists as either a small
catalytically active protein or com plexed to the ADA binding protein, recently
suggested to be the T cell activation antigen, CD26 (Van der W eyden & Kelly, 1976;
Daddona & Kelly, 1979; Daddona et al., 1984; Kameoka et al., 1993; Morrison et al.,
1993).

It is present with high enzyme activity in lym phoid tissue and the

gastrointestinal tract. An absence or deficiency of functional adenosine deaminase is
associated with severe immunodeficiency and lymphopenia in both T- and B-cell
lineages. Inherited deficiency o f the enzyme accounts for one fourth o f all severe
combined immunodeficiency disease in children (Giblett et al., 1972; Hirschhom et
al., 1979; Hirschhom et al., 1983).

The deleterious effects are believed to be

mediated by the build-up o f adenosine and deoxyadenosine in lymphoid cells, which
are converted to the ultimate toxic metabolite deoxyadenosine triphosphate (Carson
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et al., 1977; Coleman et al., 1978; Fox & Kelley, 1978; Martin & Gelfand, 1981).
The overproduction of adenosine deaminase in humans has been linked with severe
hemolytic anemia and some leukemias (Van der W eyden & Kelly, 1976; Valentine
et al., 1977; Fox & Kelley, 1978; Smyth et al., 1978). Potent inhibitors o f adenosine
deaminase have been used alone or in combination with other drugs as antimetabolic,
antineoplastic, and antibiotic agents to treat certain leukemias in hum ans (Fox &
Kelley, 1978; Coleman, 1983). Furthermore, since adenosine deaminase is a key
enzyme in adenosine metabolism, it also affects cellular levels o f adenosine, which is
an endogenous anticonvulsant and antihypoxic as well as a m odulator o f
neurotransmission, coronary blood flow, lipolysis, and glycogenolysis (Robio et al.,
1969; Bumstock, 1972; Chagoya de Sanchez et al., 1974; Fain & Wieser, 1975; Fox
& Kelley, 1978).
The catalytic mechanism o f the deam ination reaction o f adenosine and
deoxyadenosine has been the subject o f much speculation for over 20 years. A
number o f mechanisms have been proposed by different groups using ground- and
transition-state analog inhibitors (W olfenden et al., 1967; W olfenden et al., 1977;
Kurz & Frieden, 1983; Kurz et al., 1985; Frick & W olfenden, 1986; Frick et al.,
1987; Weiss et al., 1987; Jones et al., 1989; Kati & Wolfenden, 1989; Kati et al.,
1992; G rosshans & W olfenden, 1993; A dler & W olfenden, 1994).

A hydrate

tetrahedral intermediate of purine riboside was first observed in I3C NM R studies o f
calf intestine adenosine deaminase (Kurz & Frieden, 1987) and subsequently in the
X -ray cry stal stru ctu re o f m ouse

a d en o sin e

deam inase co m p lex ed

to

1,6-dihydropurine riboside (Wilson et al., 1991; Sharff et al., 1992). Time-resolved
fluorescence spectroscopy has also been used to demonstrate conformational changes
in adenosine deaminase upon inhibitor binding which may serve to stabilize the
tetrahedral intermediate (Philips et al., 1987; Philips et al., 1989). The X-ray crystal
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structure also revealed adenosine deaminase to be a metalloenzyme containing one
mole of Zn per mole of protein. The enzyme has an oc/p barrel structure consisting
of eight p strands connected by eight a helices. The active site is well-buried in the
C-terminal end o f the barrel with the Zn lying in the deepest part o f the active site
pocket. The Zn is coordinated by five atoms from H isl5, H isl7, His214, Asp295,
and 1,6-dihydropurine riboside. A catalytic mechanism was recently proposed based
on the crystal structure o f mouse adenosine deaminase bound to a ground state
analog 1-deazaadenosine (Wilson & Quiocho, 1993). An activated water molecule
attacks the substrate at the 6-position o f the purine ring to form the tetrahedral
intermediate. The Zn plays a central role in this mechanism.
The functional role o f amino acid residues in or close to the active site of
adenosine deam inase has been probed by site-directed mutagenesis o f the human
enzyme based on the X-ray crystal structure o f the mouse enzyme (W ilson et al.,
1991; Bhaumik et al., 1993). The human enzyme has 11 additional amino acids at
the C-terminus and over 80% homology with the mouse enzyme in the rest o f the
sequence. The active site residues are completely conserved. Replacement o f four
amino acid residues in the active site with alanine: His 17, His214, Glu217, and
His238, caused dramatic loss of enzyme activity though the enzyme still had a bound
Zn. The X-ray structure shows that His 17 and His214 coordinate the active-site Zn,
while Glu217 and His238 bind the ligand in the transition state. The H isl7A la and
His214Ala mutants gave very low protein yields during purification. However, the
Glu217Ala and His238Ala mutants could be isolated in excellent yield and purity.
In the recent proposed catalytic mechanism o f adenosine deaminase, Glu217 donates
a proton to N1 o f substrate adenosine. This reduces the N1— C6 double bond
character, making C6 susceptible to nucleophilic attack and transformation from sp2
to sp3 in the tetrahedral adduct. His238 acts as a general base and attracts a proton
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from a Zn-activated water to create a pre-transition state. The abstracted proton on
Ne2 of His238 then serves as a proton donor to the N6 amino leaving group of
adenosine (Wilson & Quiocho, 1993). In order to confirm the pivotal roles of
Glu217 and His238 in catalysis, it is important to establish that the loss o f enzyme
activity is not due to protein conformation changes. In this paper, protein secondary
structure changes are determined by CD spectral analysis using the convex constraint
algorithm (Perczel et al., 1992a). The binding of transition-state analog inhibitors to
wild-type and mutant human adenosine deaminases is measured in a fluorescent
assay.

The stability o f the wild-type and mutant proteins to temperature and

denaturants is monitored by CD spectroscopy. The results provide further insight
into the relationship between protein conformation and enzyme activity in adenosine
deaminase.
M aterials and M ethods
Materials. Adenosine and inosine are purchased from Sigma Chemical Co.
(St Louis, MO). Urea is ultra pure, enzyme grade from Life Technologies, Inc.
(Gaithersburg, MD).

Guanidinium chloride is ultra pure grade from Amresco

(Solon, OH). 2-aminopurine riboside is synthesized by the method o f Fox et al.
(1958). All other reagents are of the highest com m ercial grade.

Recombinant

w ild-type hum an adenosine deam inase is purified by adenosine affinity
chromatography (M edin et al., 1990; Bhaumik et al., 1993).

M utant enzymes

His238Ala and Glu217Ala are purified by using a monoclonal antibody column
(Bhaumik et al., 1993) or a purine riboside affinity column (Santoro & Bolen, 1988).
Enzyme stock solutions are stored in 10 mM sodium phosphate buffer, pH 7.4, 140
mM NaCl. Concentration ranges and specific activities for wild-type, Glu217Ala,
and His238Ala are 8.4 - 24, 2.3 - 8.1, and 2.0 - 3.3 x 10*5 M; and 450, 0.04, and 0.12
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units/mg, respectively. Protein concentration is determined by the Bradford method
and molarity is calculated using a molecular weight o f 41,000.
Circular Dichroism. Circular dichroism measurements are made on an AVTV
model 62DS spectropolarimeter equipped with a model W5TZ-105 thermoelectric
temperature controller.

Data for the respective blank solution are recorded and

subtracted from the adenosine deaminase data. The molar ellipticity [0] in deg cm2
dmol*1 is calculated from

[0] = eobsMWR/lOcl

( 1)

where 0 obs is the measured ellipticity in m illidegree, MW r is the mean residue
molecular weight o f the protein (41,000 m olecular weight divided by 363 amino
acids), c is protein concentration in mg/mL, and I is the optical pathlength o f the cell
in cm.
Secondary structure o f wild type and m utant adenosine deam inases is
determined from their CD spectra between 178 nm and 240 nm recorded using a 5 s
time constant, 0.8 nm bandwidth, scan speed o f 6 nm/min, and 0.01-mm cylindrical
fused silica cells. To improve the signal-to-noise ratio, 8 scans are averaged for each
CD spectrum to give the final data for secondary structure analysis. Enzyme samples
are dialyzed against 3 x 500 mL of 10 mM sodium phosphate buffer, pH 7.4, 140
mM NaF using Slide-A-Lyzer dialysis cassettes at 4 °C. Buffer is changed after
dialyzing for at least 5 h. The dialysis membrane has 10,000 MW cut-off (Pierce,
Rockford, IL). Final enzyme concentrations are 1.9 x 10-5, 5.5 x 10~5, and 7.0 x 10~5
M for wild type, Glu217Ala, and His238AIa, respectively. All CD spectra are
collected at 25 °C. Percentages of a-helix, P-sheet, P-tum, and random coil in the
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three-dimensional protein structure are estimated using the CCA analysis program
kindly provided by Professor. G. D. Fasman (Perczel et al., 1992a).
The convex constraint algorithm is a general deconvolution method for
analyzing a set o f CD spectra simultaneously and extracting the secondary structural
features for all o f them. The set o f CD spectra o f N proteins are stored in the
colum ns of the A[LxN] m atrix, w here L is the num ber o f w avelengths.
Deconvolution o f the A[LxN] matrix results in P pure secondary structure spectra
stored in the B[LxP] matrix and a conformational weight matrix C[PxN], which
determines the percentage o f each secondary structure spectrum in the CD spectra
stored in the A[LxN] matrix.

A[LxN] = B[LxP]*C[PxN] = D[LxN]

(2)

The A[LxN] matrix provided with the program contains the CD spectra o f 30
proteins whose X-ray structures are known.

The CD spectrum o f adenosine

deaminase is added to this 30-protein reference data set and the enlarged 31-protein
data set is analyzed in the CCA program. The last column o f the conformational
weight C[PxN] matrix contains the secondary structural percentages o f adenosine
deaminase. The product o f the B[LxN] and C[PxN] matrices reconstructs a D[LxN]
matrix at each iteration. The overall similarity o f the reconstructed spectra in the
D[LxN] matrix to the original spectra in the A[LxN] matrix is judged from the a
value.

a 2 = (Zi=i,L Sj=i,N [A(i,j)2 - D(i,j)2])/(LN)

(3)

where i is the row number denoting wavelength and j is the column number o f a
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protein spectrum in the A[LxN] and D[LxN] m atrices. The C[PxN] coefficient
matrix from the iteration with the minimum a value is then used in a Pearson product
moment calculation.

The coefficient R from the Pearson product moment

calculation represents the "similarity" betw een sets o f pairs o f num bers and
compares a reference coefficient matrix constructed from X-ray and NMR data with
the C[PxN] matrix generated by the CCA program. The R value falls in the -1< R
<+1 range, where +1 represents a perfect similarity.
Stability of wild type and mutant adenosine deaminases to thermal, urea, and
guanidinium chloride denaturations is determined from the CD at 222 nm recorded
using a 5 s acquisition time, 0.07 nm bandwidth, and 1.0-mm cylindrical fused silica
cells. Each data point is an average measured for 2 min in order to improve the
signal-to-noise ratio. Enzyme concentration is 1.7 x 10*5, 5.8 x 10-5, and 7.3 x 10'5
M for w ild type, G lu217A la, and H is238A la, respectively.

F o r thermal

denaturations, molar ellipticity is determined every 5° from 5-95 °C.

Urea and

guanidinium chloride denaturation is measured at 25 °C. Denaturation curves are
analyzed using the sloping baseline m ethod (B ecktel & Schellm an, 1987).
Thermodynamic constants are calculated assuming a two-state unfolding transition.

K = [denatured enzyme]/[native enzyme]

(4)

AG° = -RTlnK

(5)

AH0 = RT201nK /3T)P

(6)

B inding

C o n stan ts. Fluorescence m easurem ents are done at room

temperature on an SLM 8000C™ spectrofluorometer. The excitation and emission
slits are set at 4 nm. Fluorescence intensity is collected in the photon-counting ratio
mode. 4 x 10-mm cells are used for all fluorescence m easurem ents.
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fluorescence quantum yield of 2-aminopurine riboside in water is measured relative
to tryptophan in water, assuming a quantum yield for tryptophan o f 0.14. Binding of
2-aminopurine riboside to adenosine deaminase is monitored by fluorescence. In
titration experiments, 2-aminopurine riboside concentration is fixed at 18 |iM, which
gives an absorbance < 0.08 (10-mm path length) at 320 nm excitation wavelength.
Small aliquots o f adenosine deaminase are added to final concentrations o f 5-100
|iM . Relative fluorescence intensities are monitored at 370 nm emission wavelength
and corrected for background fluorescence and dilution (Birdsall et al., 1983; Harris
& Bashford, 1987). The equilibrium dissociation constant o f 2-aminopurine riboside
is determined from the fluorescence data as follows

[ADA]/(AI/AImax) = Kd/( 1 - AI/AImax) + [2-APr]0

(7)

where Al = I - IQ; AImax = Imax - lo! Io is the fluorescence intensity in the absence of
adenosine deaminase; Imax is the fluorescence intensity o f 2-aminopurine riboside
when it is saturated by the enzyme; [2-APr]0 is the total concentration of
2-aminopurine riboside. Imax is obtained from the intercept o f a double reciprocal
plot o f 1/1 vs

1/[ADA].

Kd is determ ined from the slope o f a plot o f

[ADA]/(AI/AImax) vs 1/Q -A I/A W ).
Purine riboside is another competitive inhibitor o f adenosine deaminase.
Since it is not fluorescent, the dissociation constant o f purine riboside is determined
in a competition experiment from 2-aminopurine riboside fluorescence data. Both
2-aminopurine riboside and adenosine deaminase concentrations are fixed such that
the enzyme is about 70% saturated with 2-aminopurine riboside. 2-aminopurine
riboside concentration is 22 p.M; enzyme concentration is 3.2, 5.5, and 6.2 p.M for
wild type, G lu217A la, and His238Ala, respectively.

Sm all aliquots of purine
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riboside are added to the mixture to final concentrations o f 2-120 (iM. The addition
o f purine riboside displaces 2-am inopurine riboside, which increases the
fluorescence intensity at 370 nm (Harris & Bashford, 1987). The dissociation
constant for the competitive inhibitor is determined by

AImax/AI = 1 + (Kd/[2-APr]0)( 1 + [PR]o/Kj)

(8)

where FQj is the dissociation constant o f 2-aminopurine riboside; [PR]0 is the total
concentration o f purine riboside, and K; is the dissociation constant o f purine
riboside.

A plot o f A Imax/AI vs [PR]0 yields a straight line, with intercept

[l+(Kd/[2-APr]0)] and slope (Kd/[2-APr]0) (1/K;) (Harris & Bashford, 1987).
Enzym e K inetics. Reactant adenosine and product inosine o f adenosine
deam inase-catalyzed reaction are monitored by UV spectrometry or HPLC. All
measurements are done at room temperature in 10 mM sodium phosphate buffer, pH
7.4, 140 mM NaCl. The enzyme concentrations in these assays are 8.0 x 10~10 M,
1.2 x 10’6 M, and 8.5 x 10*7 M for wild-type, Glu217Ala, and His238Ala enzymes,
respectively.

Protein concentration is determ ined using the Bio-Rad protein

microassay (H ercules, CA).

Six 1 mL reaction mixtures were prepared with

adenosine concentrations o f 5-40 |iM. In the spectrophotometric assay, the decrease
o f absorbance at 265 nm (Aea -i = 7.7 x 103 c m ^ M '1) is monitored as a function of
time in 10-mm cell in a Model 118DS AVIV Associates spectrophotometer. Initial
velocities are determ ined from the slope o f the absorbance trace (Kalckar, 1947;
Agarwal & Parks, 1978; Cercignani, 1987). In the HPLC assay, 40 |iL aliquots are
removed from the reaction mixture at different times and placed in Eppendorf tubes
in a water bath at 90 °C to stop the reaction. 20 jiL aliquots are injected into a
Rainin HPLC w ith a Rainin M icrosorb-M V C18 column and an ISCO UV
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absorption detector. The column is eluted with a gradient o f 20-80 % buffer A in 15
min. Buffer A is 95% 50 mM NaH 2 PC>4 + 5% methanol and buffer B is 50% 50 mM
N aH 2 PC>4 + 50% methanol. Inosine and adenosine elute at about 4 and 6 min,
respectively, with baseline separation at 256 nm. Concentrations of adenosine and
inosine are calculated from ratios o f peak areas and ratios o f extinction coefficients.
Kinetic constants Km and kcsl are determined from Lineweaver-Burk plots,

l/vj = 1/Vmax + KM/(Vmax [S])

(9)

kcat = V max/[E T ]

(10)

where v; is the initial velocity, [S] is total adenosine concentration, and [Et ] is total
adenosine deaminase concentration. All the kinetic constants are average values for
3-4 separate enzyme preparations.

Results and Conclusion
Secondary Structure. The CD spectra o f wild-type and mutant adenosine
deaminases show two negative bands near 208 and 222 nm and a stronger positive
band near 190 nm, typical o f a-helical structure (Figure 2.1). Both mutants give less
intense signals at those positive and negative bands. The magnitude o f the molar
ellipticity at 222 nm for Glu217Ala and His238Ala decreases about 22% and 38%,
respectively, compared to wild-type enzyme. The decrease o f ellipticity at these
wavelengths indicates loss o f a-helical structure in the m utants. Therefore, the
conformational changes in the mutants are quantified by extracting the percentages
o f different secondary structures o f w ild-type and m utant human adenosine
deaminases from the CD spectra.
The analysis of CD data is based on reference spectra o f proteins with known
structures. The convex constraint algorithm (Perczel et al., 1989; Perczel et al.,
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Figure 2.1. Circular dichroism spectra of human adenosine deaminases at 25 °C. (a)
Wild-type enzyme (— ) native, (.... ) CCA fit o f native spectrum, and (— ) renatured
after thermal denaturation. (b) Mutant enzymes (— ) Glu217Ala, (-----) CCA Fit of
Glu217Ala spectrum, (-......) His238Ala, and (..... ) CCA fit of His238Ala spectrum.
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1991b; Perczel et al., 1992a) operates on a collection of spectral data to extract the
operates on a collection of spectral data to extract the common spectral components
(a-helice, p-sheet, P-tums, etc.) with their spectral weights. These derived "pure"
CD curves can reconstruct the original data set with great accuracy. As a way of
overcom ing the bias composition o f the database, the CCA analysis varies the
num ber o f components P. Recent studies have demonstrated the success o f this
method in the secondary structure determination o f natural and synthetic peptides
and proteins (Perczel et al., 1991a; Hollosi et al., 1992; Park et al., 1992; Perczel &
Fasm an, 1992; Perczel et al., 1992b; Perczel et al., 1993).

There are two

complementary steps in evaluating the deconvolution results: (1) determination of
the number o f components and (2) assignment o f the component spectra to specific
secondary structures.
The program is run with various values of the number o f components P.
Because a run with more components would naturally have a higher probability of
regeneration o f the original data matrix, the standard deviation cr should decrease as
P increases. The rate of change of a w ith increasing P decreases exponentially with
inflection and insignificantly after the inflection point. In the analysis o f wild-type
and mutant adenosine deaminases, the inflection point occurs at four components
w ith c = 410 deg cm2 dm oH . Analyses with P = 3 and 5 give a = 830 and 360 deg
cm 2 d m o l'1, respectively. Four com ponent spectra are consistent with the X-ray
crystal structure of mouse adenosine deaminase, which contains a-helix, P-sheet, P
turns, and random conformations. The "pure" component spectra o f wild-type and
mutant adenosine deaminases obtained from the CCA program for the P = 4 analysis
have the following characteristics. The a-helix spectrum has a positive peak at 192
nm (n-n* transition), with molar ellipticity o f 67,000 to 72,000 deg cm 2 d m oH and
two negative peaks at 208 (rc-7t* transition) and 222 (n-7t* transition) nm o f -34,000
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to -37,000 deg cm 2 dmol*1. The (3-sheet spectrum has a positive peak around 197 nm
(j i —k * transition) of 43,000 to 46,000 deg cm 2 dmol*1, and a negative peak at 216 nm
(n- Jt* transition) o f -14,000 to -17,000 deg cm 2 dm ol*1. The (3-turn spectrum
resembles that o f the a-helix only with smaller molar ellipticities (39,000 to 41,000
deg cm2 dmol*1 at 192 nm, -8,000 to -9,000 deg cm2 dmol*1 at 208 and 222 nm).
The random conformation has a large negative band around 200 nm o f -18,000 to
-19,000 deg cm 2 dmol*1 and a small positive peak at 220 nm o f 550 to 610 deg cm2
dmol*1.
The secondary structural percentages obtained from the coefficients in the
weight matrices C[PxN] for wild-type and mutant human adenosine deaminases, as
well as the respective Pearson product moment coefficients R, are summarized in
Table 2.1. The secondary structural percentages o f mouse adenosine deaminase
computed from the X-ray structure are also listed for comparison. Wild-type human
enzyme has sim ilar but slightly higher percentages o f a-helix and (3-sheet than the
mouse enzyme. W hile a-helical structure is partially lost in the active-site mutants
of the human enzyme, Glu217Ala and His238Ala, the P-sheet structure seems to be
completely intact. The values of the Pearson product moment coefficient R for the
CCA analyses o f wild-type, Glu217Ala, and His238Ala adenosine deaminases are
0.86, 0.73, and 0.76, respectively, showing very good agreement between the
secondary structural percentages obtained from CD and X-ray data o f the 30
reference proteins. Human adenosine deaminase has 11 more amino acid residues at
the C-terminus than mouse adenosine deaminase. Assuming that the C-terminal tail
o f human adenosine deaminase is fully a-h elical, 3% o f the a-helical structure
would come from the extra tail. Subtracting a 3% contribution from the tail gives
48% a-helical structure for wild-type human adenosine deaminase, which is very
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Table 2.1. Secondary structure percentages of human adenosine deaminases predicted from CD spectra using convex
constraint algorithm method.

a-helix

P-sheet

p-turns

random coil

Rp

wild-type

51 ± 2

13 ± 1

11 ± 2

25 ± 2

0.86

Glu217Ala

35 ± 2

15 ± 2

8±2

42 ± 2

0.73

His238Ala

27 ± 1

14 ± 2

6±3

53 ± 2

0.76

46

11

15

28

enzyme

mouse wild-type“

prohibited without perm ission.

“Wilson et al., 1991; 1993.

U>
Q\
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close to the 46% a-helical structure for the mouse enzyme. The active-site mutants
Glu217Ala and His238Ala have lost 33% and 50% o f their a-h e lica l structures
compared to wild type human enzyme. The a-helical regions in the X-ray structure
of mouse adenosine deaminase comprise the outside o f the (3 barrel and the lid on the
top o f the barrel. The active site itself is situated in the bottom o f the barrel. The
P-sheet structure is preserved in the mutant enzymes, suggesting that the active site is
largely extant.
In h ib ito r B in d in g . Changes in the enzym e active site pocket upon
substitution o f Glu217 and His238 are examined by inhibitor binding studies (Figure
2.2). 2-aminopurine riboside is a transition-state analog o f the adenosine substrate; it
is a fluorescent competitive inhibitor o f adenosine deaminase (Kurz et al., 1992). It
has a fluorescence quantum yield o f 0.65 in aqueous solution with an emission
maximum at about 370 nm. The fluorescence is quenched 60% upon binding of
adenosine deaminase (Table 2.2). The binding constants o f 2-aminopurine riboside
and purine riboside to w ild-type and mutant human adenosine deaminases are
determined by a fluorescent assay (Table 2.2). The dissociation constants Kd of
2-aminopurine riboside and purine riboside are 2 (lM for the wild-type enzyme. The
kinetic constants o f the wild-type and mutant enzymes are determ ined by two
methods with adenosine as substrate: UV spectrometry (Kalckar, 1947; Agarwal &
Parks, 1978; Cercignani, 1987) and HPLC. Table 2.3 gives the results along with
literature values from a radiochemical assay using [14C] adenosine (Coleman &
Hutton, 1975; Bhaum ik et al., 1993). The inhibition constants K, of wild-type
enzyme are determ ined for 2-aminopurine riboside and purine riboside by UV
spectrometry. The K; values are identical to the Kd values (Table 2.2). Wild-type
human adenosine deaminase appears to have 2- to 4-fold higher affinity for purine
riboside than the w ild-type enzymes from calf intestine (Kurz et al., 1992) and
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Table 2.2. Dissociation and inhibition constants (pM) of 2-aminopurine riboside and purine riboside.

prohibited without perm ission.

Glu217Ala

His238Ala

60.2 ± 0.8

58.8 ± 0 .7

57.8 ± 0 .8

K d(|iM )

1.7 ± 0 .3

3.9 ± 0 .5

5.7 ± 0 .6

Kj (pM)

1.9 ± 0 .3

ND°

ND«

Kd (pM)

2.3 ± 0 .4

2.9 ± 0 .6

4.6 ± 0.6

Ki (pM)

2.1 ± 0 .5

NDa

NDa

inhibitor

wild-type

2-aminopurine riboside
% Almax/Io

purine riboside

aNot determined.

U)
VO
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Table 2.3. Kinetic constants of human adenosine deaminases.

enzyme assay

wild-type

Glu217Ala

His238Ala

HPLC
Km (|iM)
fccat (sec-1)

23 ± 4
331 ± 3

12 ± 3
0.020 ±0.001

6.9 ± 0.5
0.1 ±0.003

UV spectrometry
Km (l^M)

prohibited without p erm ission.

fccat ( s e c 1)

20 ± 3
308 ± 5

11 ± 4
0.02 ±0.001

5.4 ± 0 .3
0.1 ±0.003

radiochemical0
Km (HM)
kcat ( s e c 1)
°Bhaumik et al., 1993.

27 ± 4
320

18.5 ± 3 .4
0.03

8.0 ± 0.5
0.1
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mouse (Mohamedali et al., 1996), respectively. It binds 2-aminopurine riboside with
the same affinity as the wild-type calf enzyme (Kurz et al., 1992). However, the Km
values of all these wild-type enzymes for adenosine substrate are the same: human
Km = 22 ± 4 jiM (Table 3), calf Km =19 jiM (Kurz et al., 1992), and mouse Km = 19
± 4 jiM (Mohamedali et al., 1996).
The Glu217Ala mutant of human adenosine deaminase binds purine riboside
w ith the same affinity as wild-type enzym e. However, the binding affinity for
2-aminopurine riboside is decreased 2-fold in the mutant compared to wild-type.
The His238Ala mutant, on the other hand, gives consistently larger K<j values for
both purine riboside and 2-aminopurine riboside, binding the inhibitors with 2- to
3-fold lower affinity than wild-type enzyme. The wild-type and m utant adenosine
deaminases quench 2-aminopurine riboside fluorescence to the same extent (less than
3% difference), suggesting that the inhibitor binding sites are similar. These results
suggest that the binding determinants in the enzyme active site are only slightly
disturbed by the Glu217 and His238 mutations, despite substantial loss o f a-helical
structure in the mutant enzymes. A series o f mutants with Glu217 replaced by Asp,
Gly, Gin, and Ser have been made in mouse adenosine deaminase (M ohamedali et
al., 1996). In the mouse enzyme, the inhibition constant K; for purine riboside is also
not changed by substitution at Glu217.
The Kd values of the human adenosine deaminase mutants indicate slightly
decreased inhibitor binding affinities with wild-type > Glu217Ala > His238Ala.
Previous kinetic studies using a radiochem ical assay, however, show sm aller Km
values for these mutants than for the wild-type enzyme (Bhaumik et al., 1993),
suggesting that the mutants have higher affinity for substrate w ith His238Ala >
G lu217Ala > wild-type. We measured the kinetic constants for several different
enzyme preparations o f wild-type and mutant human adenosine deaminases by two
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different assays, UV spectrometry and HPLC, and confirm ed the lower Km values
for the mutant enzymes. The Michaelis constant Km equals the dissociation constant
IQ when the rate of dissociation o f enzyme-substrate complex is much faster than the
catalytic rate Q at. The kcat values are decreased 15- and 3.2- thousandfold for the
G lu217Ala and His238Ala mutants, respectively, com pared to the wild-type fccat
(Table 2.3). In principle, Km values should be better approximations o f IQ in the
mutants than in the wild-type enzyme. The inverse order o f binding affinity for
substrate and transition-state analog inhibitors in the wild-type and mutant adenosine
deaminases invites comment. First, the Km values for mutant adenosine deaminases
may be inaccurate due to the difficulty o f measuring very low levels of enzyme
activity. This seems unlikely in view of the good agreem ent in the results from
different assay methods.

Second, the Ala substitutions in the active site may

improve substrate binding, while weakening inhibitor binding. Third, Glu217Ala
has the same affinity for purine riboside as the wild-type enzyme. If the affinity for
substrate were also the same in the two enzymes, then the Km value of Glu217Ala
would provide a better estimate of IQ than the wild-type Km value. Fourth, the
binding determinants for substrate and inhibitors may be different. However, the
substrate and inhibitor binding affinities in the His238Ala mutant are almost the
same, which implies that the binding determinants for these compounds are similar.
Mohamedali et al. (1996) report that wild-type and Glu217 mutant mouse
adenosine deam inases lost enzyme activity upon storage in phosphate buffer.
Therefore, both wild-type and mutant mouse enzymes were purified in the presence
o f exogenous Zn and stored in Tris buffer containing 10 |iM Zn2+. We find no
evidence for loss of Zn from wild-type or mutant human adenosine deaminases
(Bhaumik et al., 1993). First, Zn determination using flame atomic absorption
spectrom etry dem onstrated that wild-type, G lu217A la, and His238Ala human
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adenosine deaminases contain one mol o f Zn2+ per mol o f protein. Graphite furnace
atomic absorption gave 2 mol o f Zn2+ per mol o f protein, purportedly due to
inaccuracies in Zn2+ determ inations on small quantities o f protein.

Second,

phosphate buffer was replaced with Tris buffer in the enzym e purifications.
W ild-type and mutant adenosine deaminases were purified in the absence and
presence of exogenous Z n2+. The use o f a non-Zn-chelating buffer containing
exogenous Zn resulted in a very small (0.05-0.12%) increase in wild-type enzyme
activity, but did not increase Glu217Ala or His238Ala m utant activity.

Third,

wild-type, Glu217Ala, and His238Ala adenosine deaminases were purified in a onestep procedure on a monoclonal antibody column eluted w ith 4-6 M urea.

A

two-column purification procedure on DEAE-Sephadex and adenosine- or purine
riboside-Sepharose was also used for comparison. Neither wild-type nor the two
mutants exhibit differential enzyme specific activities due to purification method.
Thus, in the case o f human adenosine deaminase, the wild-type and mutant enzymes
in phosphate buffer have a Zn molecule in the active site.

Perhaps the human

enzyme binds Zn more tightly than the mouse enzyme.
Protein Stability. The sizable changes in secondary structure o f the mutant
human adenosine deaminases have no effect on Zn binding and only modest effects
on substrate and inhibitor binding in the enzyme active site. This strongly suggests
that replacement o f key amino acid functional groups, not the structural changes, is
responsible for the dramatic loss in enzyme activity. This raises a question about the
role o f the fraction of a-helical structure in adenosine deaminase that is lost in the
mutant enzymes. A simple way to examine the effect of specific amino acids on
protein structure is to compare the stability of wild-type and mutant proteins. We
therefore measure the relative stabilities o f wild-type, GIu217Ala, and His238Ala
hum an adenosine deam inases to therm al, urea, and guanidinium chloride
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denaturation by monitoring the CD at 222 nm. O f the two negative a-h elix CD
bands, 222 nm avoids the significant UV absorption o f urea and guanidinium
chloride below 210 nm wavelength. The baseline dependencies o f CD signals on
temperature and denaturant concentrations are linear with fairly small slope (<0.2%).
The denaturation profiles are analyzed assuming a tw o-state reversible
transition, in which only the native and fully-denatured conformational states are
substantially populated and the p artially folded interm ediate states are
thermodynamically unstable. The thermal denaturation curves for wild-type and
mutant human adenosine deaminases show a single-step pattern (Figure 2.3),
indicating a two-state transition (Pace, 1986). The cooperative melting transition of
wild-type enzyme is 92% reversible, as judged from the CD spectrum after slow
cooling (Figure 2.1). Two-state transition curves are also obtained upon urea and
guanidinium chloride denaturation (Figures 2.4 and 2.5). The urea denaturation is
reversible. One o f the two methods used to purify the protein involves treatment
with 4-6 M urea (Bhaumik et al., 1993). None o f the enzymes exhibit differential
specific activities in the two purification methods, indicating that the enzymes are
fully refolded after removal of urea. Addition o f 20 p.M Zn2+ during urea treatment
changes neither the magnitudes of the molar ellipticities nor the denaturation profiles
for wild-type and mutant enzymes. The denaturation curves o f all three unfolding
processes for wild-type, Glu217Ala, and His238Ala adenosine deam inases are
quantitatively fit to the two-state constant ACp or AG models described previously
(Schellman et al., 1981; Pace, 1986).
Wild-type adenosine deaminase has a high melting temperature Tm o f 70 °C,
making it very stable with respect to thermal denaturation. The mutants are also
quite heat resistant, but not as stable as wild-type enzyme (Figure 2.3). Glu217Ala is
more stable than His238Ala; the m elting tem peratures are 65 and 60 °C,
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respectively. Thermodynamic constants for thermal unfolding are calculated from
the Van't Hoff equation. The enthalpy change for the transition is obtained from eq 6
(Table 2.4). The enthalpy changes for thermal denaturation o f adenosine deaminases
are positive, with AH(wt) > AH(GIu2I7AIa) > AH(His238Ala).
Urea denaturation reactions are monitored at 25 °C. The Gibbs free energy
of protein unfolding, AG, is calculated from eq 5. For a two-state transition, AG
varies linearly with denaturant concentration (Pace, 1986). The data are fit by linear
regression to the following equation:

AG = AG(H20) + k [denaturant]

(11)

where AG(H 2 0 ) is the free energy o f protein unfolding in the absence of denaturant
and k is a measure o f dependence o f AG on denaturant concentration.

The

concentrations at the denaturation midpoint Cm o f w ild-type, GIu217Ala, and
His238Ala are 5.3, 4.2, and 3.7 M urea, respectively (Figure 2.4). All A G (H 20)
values are positive (Table 2.4): AG(wt) > AG(Glu217Ala) > AG(His238Ala). The
relative stabilities of wild-type and mutant enzymes to thermal and urea denaturation
are the same.
Both wild-type and mutant human adenosine deaminases begin to unfold at
very low concentrations of guanidinium chloride (<0.2 M). Wild-type, Glu217Ala,
and His238Ala seem to show different denaturation profiles, though all appear to be
single-step processes. For Glu217Ala the unfolding transition appears somewhat
less cooperative than for wild-type and His238Ala. The m olar ellipticity changes of
wild-type enzyme have a midpoint at about 1.2 M and a total loss o f secondary
structure above 1.5 M guanidinium chloride (Figure 2.5).

The midpoints for

Glu217Ala and His238Ala mutants are l.l and 0.4 M, respectively. The AG values
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are fit to eq 11 assuming a two-state transition for all three proteins in guanidinium
chloride. All A G(H20) values are positive (Table 2.4), but the order is different:
AG(Glu217Ala) = AG(wt) > AG(His238Ala). Although the Glu217Ala mutant gives
a slightly higher AG(H 2 0 ) value than wild-type, the wild-type enzyme has a slightly
higher midpoint for denaturation.

The sloping baseline method used here for

calculation o f AG involves the extrapolation o f pre- and post-transition regions,
which underestimates the error in the parameters determ ined because no error is
assumed for the pre- and post-transition baselines (Santoro & Bolen, 1988). Possibly
that accounts for the inverse order o f Cm and AG(H 2 0 ) values for the wild-type and
Glu217Ala mutant.

The stability o f wild-type and G lu217A la to guanidinium

chloride denaturation is about the same.
The estimates o f AG(H20) o f wild-type, Glu217Ala, and His238Ala human
adenosine deaminases derived from guanidinium chloride unfolding experiments are
greater than those from the urea unfolding experiments, which result from stronger
binding of guanidinium chloride to the folded proteins. Also, the molar ellipticities
of the final unfolded states for urea (about -4,200 deg cm 2 dm ol'1) and guanidinium
chloride (about -5,800 deg cm 2 dmol*1) denaturation are different, indicating that the
unfolded states of the proteins in urea and guanidinium chloride solutions may differ
significantly in the extent o f interaction with denaturant. The ellipticity for thermal
denaturation plateau is -5 ,000 deg cm2 dm ol'1. The final unfolded states for the
three proteins appear to approach almost the same plateau value in each solvent,
indicating that the wild-type and mutant enzymes reach the same unfolded state in
each denaturation process.

The relatively m inor differences among m olar

ellipticities of unfolded states o f wild-type and mutant adenosine deaminases in each
denaturation process are within experimental error (±1,000 deg cm2 dm ol'1).
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denaturant

wild-type

Glu217Ala

His238Ala

thermal
AH (kJ/mol)
AAH (kJ/mol)
Tm (°C)

340 ± 2

335 ± 3

0

5

330 ± 3
10

70 ± 1

65 ± 1

60 ± 1

23 ± 1

12 ± 1

3± 1

urea
AG(H20) (kJ/mol)

prohibited without perm ission.

AAG (kJ/mol)

0

Cm (M)

5.3 ± 0 .2

11
4.2 ± 0.2

20
3.7 ± 0 .3

guanidinium chloride
AG(H20) (kJ/mol)

17 ± 2

AAG (kJ/mol)

0

Cm (M)

1.2 ± 0.1

19 ± 3
-2
1.1 ±0.1

11 ± 3
6
0.4 ±0.1

O
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Further Discussions. Human adenosine deaminase shows extensive overall
sequence similarity (83% identical residues in the first 352 amino acids) w ith its
mouse counterpart (Chang et al., 1991). The two enzymes have identical residues
directly or indirectly involved in inhibitor binding. The X-ray crystal structure of
mouse adenosine deaminase contains a parallel a/p-barrel motif with eight central Psheet strands and eight peripheral a helices (W ilson et al., 1991; Sharff et al., 1992;
Wilson & Quiocho, 1993). The enzyme also has five additional a-helices outside the
barrel: H I, H2; H3 between p i and a l ; and H4 and H5 after a 8 . The adenosine
deaminase barrel has a "lid" structure on the top with the Zn buried at the bottom.
The lid is composed o f two parts: H3 a-helix on one side and a loop between P3 and
a3 on the other side.
From the crystal structure of mouse adenosine deaminase, it is not obvious
why replacement o f G lu2I7 and His238 should cause loss of a-helical structure.
Glu217 is located in the loop between P5 and a 5 o f the a/p-barrel and its carboxyl
group is roughly coplanar with the inhibitor bound at the active site. Apart from its
function o f donating a proton to the 1 position o f the purine ring, Glu217 is
structurally linked with two a helices. The carboxyl side chain is within van der
Waals distance o f three amino acids in the C-terminal end o f a 5 as well as o f three
amino acids in the loop lid. Additionally, Glu217 is within 5 A of three amino acids
in the H3 a-helical lid of the active site. His238 is the last o f three residues in p6 of
the barrel. The imidazole ring is within van der W aals distance of four amino acids
in a 6 as well as three amino acids in a8 and H4 a helices. His238 is also within 6 A
of the H3 a-h elical and loop lids of the barrel.

In the cases o f Glu217Ala and

His238Ala mutants, the loss of a-helical structure may come in part from helices
external to the a /p barrel, which account for about 40% of the a-helical structure of
adenosine deaminase. This would rationalize our finding that the conformational
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changes in the mutants destabilize the protein with only m inor affects on ligand
binding. On the other hand, the ligand binding determinants are all on P-sheets or
turns: (31, (35, p8; turns between p i and H I, P2 and a2 . It is possible that the barrel
remains intact with some o f the outside helices disordered.
The binding constants for purine riboside and 2-am inopurine riboside to
wild-type adenosine deaminase are apparent binding constants (Jones et al., 1989).
These inhibitors are unhydrated in solution, but are immediately hydrated in the
enzyme active site to form the respective 1,6-dihydropurine riboside (Kurz et al.,
1992). The GIu217 mutants o f mouse adenosine deaminase do not hydrate purine
riboside to form the tetrahedral interm ediate that occurs in the wild-type
enzyme-inhibitor complex (Mohamedali et al., 1996). The Glu217Ala mutant o f
human adenosine deaminase is thus not expected to form the hydrate. The mutant
enzyme binds the unhydrated purine riboside and 2-aminopurine riboside in a single
step to give a true binding constant for a ground-state analog inhibitor.

The

His238Ala mutant lacks the proposed proton acceptor for the incoming hydroxyl that
hydrates purine riboside in the enzyme active site (Wilson & Quiocho, 1993). This
mutant is not expected to form the tetrahedral interm ediate efficiently, so the
observed binding constants for purine riboside and 2-aminopurine riboside could
likewise be considered true binding constants o f ground-state inhibitors.
Inherited deficiency o f adenosine deaminase accounts for about one-fourth of
SCID in humans. DNA sequences have been reported for the defective adenosine
deaminase genes from six cell lines derived from SCID patients (Bonthron et al.,
1985; Valerio et al., 1986; Akeson et al., 1987; Akeson et al., 1988; Hirschhom et
al., 1989). The lack o f adenosine deaminase protein is the reason for the enzyme
deficiency in the patients. Normal levels of mutated mRNA are present in the cells,
but the proteins are rapidly degraded after translation.

None o f these defective
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human adenosine deaminases are active site mutants: four of the substituted amino
acids are buried residues and two are surface residues (Wilson et al., 1991). In the
Glu217Ala and His238Ala mutants, the loss o f a-helical structure destablizes the
proteins and makes them more susceptible to degradation by proteases in the
baculovirus expression system. The yields o f Glu217Ala and His238Ala are 30 and
15%, respectively, of the wild-type enzym e as isolated by two different protein
purification methods (Medin et al., 1990; Bhaumik et al., 1993). Thus, substitutions
o f amino acids in the active site as w ell as elsewhere in adenosine deam inase
apparently have profound effects on enzyme structure and stability.
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CHAPTER 3: ZN-BINDING LIGANDS AT THE ACTIVE SITE OF HUMAN
ADENOSINE DEAMINASE: AN EXAFS INVESTIGATION

Introduction
Human adenosine deaminase is a ubiquitous Zn metalloenzyme that catalyzes
the irreversible hydrolytic deamination o f adenosine and deoxyadenosine to produce
inosine and deoxyinosine, respectively, as part o f the purine salvage pathway.
A denosine deam inase is found on the surface and in the cy to p lasm o f
microorganisms and mammalian cells in several molecular and electrophoretic forms
(Spencer et al., 1968; Edwards et al., 1971; Akedo et al., 1972; Osbome & Spencer,
1973; Hirschhom, 1975; Schrader et al., 1976; Van der W eyden & Kelly, 1976;
Carson et al., 1977; Daddona & Kelly, 1977; Schrader & Stacy, 1977; Wiginton
et al., 1981).
The X-ray crystal structures o f mouse adenosine deaminase have been
d eterm in ed

fo r

c o m p le x es

w ith

a

tra n sitio n -sta te

a n alo g

in h ib ito r

6(R)-hydroxyl-l,6-dihydropurine riboside (Wilson et al., 1991; Sharff et al., 1992), a
ground-state analog inhibitor 1-deazaadenosine (Wilson & Quiocho, 1993), and
product inosine (W ilson & Quiocho, 1994). The core of the enzyme is constructed
with eight (3 strands connected by eight peripheral a helices, to form a parallel
a/p-barrel motif. The structure also has five additional a helices, three located
between P 1 and a l and two al the C-terminus. The catalytic site is located at the
carboxy end o f the P-barrel inside the pocket. The narrow opening o f the pocket is
partially capped by a loop on one side and an a helix on the opposite side. The
crystal structure also reveals the presence of an active-site Zn, which lies in the
deepest part o f the pocket at the carboxy end of the P barrel. The Zn is coordinated
by five atoms: three N82 atoms from His 15, H isl7, and His214, one 0 8 2 atom from
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Asp295, and the 0 6 atom from the transition-state analog HDPR or a hydroxide (or
water) O in the case of ADA-DAA complex. The presence o f an axial hydroxyl
covalently bonded to C-6 o f purine riboside in ADA-HDPR complex confirms the
tetrahedral intermediate observed by 13C NMR (Wilson & Quiocho, 1994).
A new enzyme catalytic m echanism was therefore proposed based on the
crystal structures o f mouse adenosine deaminase, in which Zn plays a crucial role by
facilitating formation of a pre-transition state with a bound activated water molecule
or a hydroxide (Wilson & Quiocho, 1993). In this mechanism, Glu217 donates a
proton to N1 o f substrate adenosine, thereby reducing the N1-C6 double bond
character and rendering C6 susceptible to nucleophilic attack and transformation
from sp2 to sp3 in the tetrahedral adduct. A Zn-activated water or hydroxide is the
attacking nucleophile. His238 acts as a general base/acid and plays an important role
in enzyme catalysis. Activation o f the water involves coordination o f the oxygen to
the powerful Zn electrophile, donation o f one hydrogen to a hydrogen bond with 051
o f Asp295, and donation o f the other hydrogen to a hydrogen bond with Ne2 of
His238. The abstracted proton on Ne2 o f His238 attacks the N6 amino leaving
group.
Human adenosine deaminase has 11 additional amino acids at the C-terminus
and 83% homology with the m ouse enzym e in the rest o f the sequence with
com pletely conserved active-site amino acid residues.

Active-site amino acids

Glu217 and His238 were previously substituted with alanine by site-directed
mutagenesis o f human adenosine deam inase (Medin et al., 1990; Bhaumik et al.,
1993). The active-site mutants Glu217Ala and His238Ala o f human enzyme show
little or no change in Zn content and Km values, yet dramatic loss of enzyme activity
(Bhaumik et al., 1993; Zeng et al., 1996). Dissociation constants for transition-state
analog inhibitors 2-aminopurine riboside and purine riboside are similar for
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wild-type and m utant enzymes, suggesting that inhibitor and substrate binding
determinants are preserved in the mutants (Zeng et al., 1996). I3C NMR shows that
GIu217 mutants o f mouse adenosine deaminase do not hydrate purine riboside to
form the tetrahedral intermediate HDPR (Mohamedali et al., 1996).
X-ray absorption spectroscopy has becom e an im portant quantitative
experimental technique to examine the intim ate environment o f specific metal
centers in a variety o f metalloproteins. The extended X-ray absorption fine structure
provides detailed information on the first coordination shell of the excited metal
atom: the metal-Iigand distances and the type and coordination number o f ligands
(Stern, 1974; Teo, 1980; Lee et al., 1981; Fay et al., 1988; Sharpe, 1990; Gamer,
1991; Lida, 1991). However, the short-range, single scattering EXAFS has serious
limitations, especially in the cases o f metalloproteins. When atoms (including the
X-ray absorbing atom and its neighbor) are arranged in a linear or near collinear
fashion, such as CN- or CO- in imidazole or carboxyl, the forward scattering is
strongly enhanced and EXAFS contributions from neighboring atoms as far as 8 A
can be observed (Teo, 1981).

The single-scattering theory o f EXAFS is not

applicable in these situations and m ultiple-scattering processes involving the
intervening atoms should be taken into account in order to provide accurate
structural characterization of the ligands bound to the metal center.
EXAFS has proved to be a particularly valuable and direct probe o f the
environment of Zn atoms, since Zn is silent in magnetic resonance and other
spectroscopic methods (Cramer, 1987). EXAFS studies at the Zn K a-absorption
edge of metalloproteins have in recent years contributed to the identification of metal
ligands in Zn proteins (Sim olo e t al.,

1986; G arner & Feiters,

1987;

Eggers-Borkenstein et al., 1989; Feiters & Jeffery, 1989; Navaratnam et al., 1989;
Dent et al., 1990; Chance et al., 1992; Zhang et al., 1992; Randall et al., 1993; Zhang
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& Auld, 1993; Bracey e t al., 1994; Rowlett et al., 1994; Thorvaldsen et al., 1994;
Ball et al., 1995; Liu et al., 1995; Priggemeyer et al., 1995; Garcia et al., 1996). The
oscillations in the X -ray absorption coefficient after the Zn Ka -edge step are
described by interference effects on the central absorber Zn atom, due to the fact that
the photoelectron w ave leaving the excited Zn atom is backscattered by the
Zn-binding ligands (Stem , 1974). Phase-corrected Fourier transformation o f the
EXAFS with respect to exp(-i2xR), where fcis the photoelectron wave vector, and R
is the absorber-backscatterer distance, gives the radial distribution function around
the absorber Zn (Sayers et al., 1971). From analysis of the EXAFS, ligand distances
(short-range, within 4 A) and coordination numbers may be derived with accuracies
o f ± 0.02 A (Citrin et al., 1976) and 15% (Eisenberger & Lengeler, 1980),
respectively.
Given the case o f adenosine deaminase, EXAFS offers a powerful technique
to address several im portant questions about the active-site Zn.

W hat is the

coordination sphere of the catalytic Zn o f human adenosine deaminase? Are there
five ligands coordinating the Zn, one o f which is an "activated water" as suggested
by the X-ray structure o f mouse adenosine deaminase? How does the structure
around the Zn change upon binding o f ground- and transition-state analog inhibitors?
What are the implications o f these conformational changes for enzyme catalysis?
What can structural studies o f the active-site Zn in Glu217AIa and His238Ala
mutants tell us about the functional roles o f these amino acid residues in the catalytic
mechanism? In this paper we present the results o f EXAFS o f the wild-type and
mutant human adenosine deaminases and their complexes with ground-state analog
inhibitor 1-deazaadenosine and transition-state analog inhibitor purine riboside. The
EXAFS data are analyzed with the Cerius2 program using the curved wave theory
(Gurman et al., 1984; Gurman et al., 1986) and the small atom theory (Gurman,
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1988) multiple scattering. The X-ray coordinates o f mouse adenosine deaminase
with bound 1-deazaadenosine or HDPR provide the starting geom etry for the
calculations (W ilson et al., 1991; Wilson & Quiocho, 1993). Zn-ligand coordination
number and distances are obtained for wild-type and mutant enzymes in the absence
and presence o f inhibitors. Comparison o f the EXAFS results for the various
enzyme forms supports the proposed mechanism for adenosine deaminase.

Materials and Methods
Materials. Trichoplusia ni (cabbage looper) larvae infected with recombinant
baculovirus containing the coding sequence for human adenosine deaminase were
produced by methods described previously (M edin et al., 1990). Benzam idine,
phenylm ethylsulfonyl fluoride, leupeptin, pepstatin, protamine sulfate, purine
riboside, and Epoxy Activated Sepharose 6B are purchased from Sigm a Chemical
Co. (St Louis, M O). Ammonium sulfate is ultrapure grade from ICN (Aurora,
Ohio).

D EA E Sephadex A-50 is a Pharm acia (Uppsala, Sw eden) product.

1-deazaadenosine is prepared according to Antonini et al (Antonini et al., 1984). All
other reagents are o f the highest commercial grade. Enzyme stock solutions are
stored in 50 mM Tris buffer, pH 6.8, 0.15 M NaCl, 40% glycerol (OmniSolv,
EMScience, Cherryhill, New Jersey) at -20 °C. Concentration ranges and specific
activities for wild-type, Glu217Ala, and H is238Ala stock solutions are 8.4 - 24,
6.2 - 8.5, and 2.8 - 3.6 x 10‘5 M; and 450, 0.02, and 0.13 units/mg, respectively.
Protein concentration is determined by the Bradford method and m olarity is
calculated using a molecular weight of 41,000.
Protein Purification . Wild-type human adenosine deaminase is purified by
adenosine affinity chromatography (Schrader et al., 1976; Medin et al., 1990).
G lu217A la and H is238Ala mutants are purified by purine riboside affinity
chromatography (Ogawa et al., 1987; Aran et al., 1990). About 25 g of frozen larvae
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stored at -70 °C are added to 80 mL of extraction buffer containing 10 mM sodium
acetate, pH 6.4, 10 mM 2-mercaptoethanol along with four protease inhibitors: 5 mM
benzamidine, 3 mM phenylmethylsulfonyl fluoride, 20 (iM leupeptin, and 8 fiM
pepstatin. The larvae are homogenized on ice using a Tekm ar tissuemizer SDT set at
medium speed with 3-15 s bursts. The homogenate is treated w ith 0.104 g of
protamine sulfate to remove viral DNA that may inhibit the binding o f adenosine
deaminase to the DEAE-Sephadex column. Subsequent steps are carried out at 4 °C.
After gentle stirring for 30 min, the homogenate is centrifuged at 15,000 rpm for 30
min. The supernatant is filtered through four layers o f cheesecloth. The clarified
supernatant is then diluted with an equal volume o f wash buffer consisting o f 10 mM
sodium acetate, pH 6.4, and is applied to a 5 x 10 cm DEAE-Sephadex A-50 column
(Bio-Rad) pre-equilibrated with wash buffer. The column is washed with 1 L of
wash buffer and the mutant protein is batch eluted with wash buffer containing 0.5 M
NaCl.

The eluate is brought to 70% saturation with am m onium sulfate and

centrifuged at 10,000 rpm for 20 min. The am m onium sulfate precipitate is
resuspended in a minimal volume o f 50 mM Tris buffer, pH 6.8, 0.15 M NaCl and
loaded onto a 1.5 x 60 cm purine riboside Sepharose 6B colum n equilibrated with
Tris buffer. The protein is eluted with 50 mM Tris, pH 6.8, 0.15 M NaCl at a flow
rate o f 0.12 mL/min. Approximately 200-5 mL fractions are collected and analyzed
by SDS-polyacrylamide gel electrophoresis (Laemmli, 1970). Approximately 100
fractions containing the 41 kDa mutant protein are pooled and concentrated to 0.5-1
mL by ultrafiltration using an Amicon Model 52.

G lycerol is added to the

concentrated enzyme solution to about 40% v/v. Enzyme activity is measured by a
radiochemical enzyme assay using 14C-adenosine (Coleman et al., 1978) Protein
concentration is determined by the Coomassie Brilliant Blue G-250 binding method
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(Bradford, 1976) with bovine serum albumin as standard and protein microassay dye
reagents purchased from Bio-Rad.
Protein Sam ple Preparation for EXAFS. 10 mg o f wild-type, Glu217Ala,
and His238Ala human adenosine deaminases are concentrated to 60 (iL at 4 °C using
M icrocon-10,000 clinical sample concentrators (A m icon) and an E ppendorf
microfuge. 40 jiL o f ethylene glycol is added to give a final protein concentration of
about 2.5 mM. The resulting 100 (J.L protein samples are loaded with a Hamilton
syringe into rectangular lucite cells with a 1 mm path length and Kapton foil
windows. The EXAFS samples are stored and transported frozen in liquid nitrogen
prior to EXAFS experiments. No changes in either the near edge or the EXAFS
region are observed during data collection, which typically lasts about 12-18 h per
sample, indicating that the X-ray radiation does not seem to cause any significant
damage to the proteins.
EX A FS. Zn K-edge X-ray absorption spectroscopic data are collected on
beamline VII-3 at the Stanford Synchrotron Radiation Laboratory for wild-type and
Glu217Ala m utant adenosine deaminases and on beamline X10-C at the National
Synchrotron Light Source at Brookhaven National Laboratory for His238Ala mutant.
X-ray absorption spectra are recorded over the energy range 9500-10400 eV for Zn
K-edge at 10 K using an Oxford Instruments CF1208 liquid He cryostat. Internal
photon energy is calibrated by simultaneously collecting a transmission spectrum of
a Zn foil and assigning its first inflection point energy to 9659.0 eV. On beamline
VD-3 at SSRL, Zn K-edge X-ray absorption spectra are collected on an unfocused
multipole w iggler beam under dedicated ring conditions (3.0 GeV, 50-100 mA)
using a Si(220) double-crystal monochromator. At NSLS, the beamline X10-C is
run in the focused mode with a Si(l 11) double-crystal monochromator. The typical
energy resolution o f these monochromators is about 1 eV. The rejection o f higher

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

order harmonics in the incident beam is accomplished by using a mirror position
feedback system (Sansone et al., 1991). Incident beam intensity is monitored with a
nitrogen gas-filled ionization chamber. XAFS data are recorded in the fluorescence
excitation mode (Jaklevic et al., 1977) using a Canberra Industries 13-element Ge
solid-state array detector with single channel analyzer windows set on the Zn K<x
fluorescence signal(Cramer et al., 1988). Copper foils are placed in front of the
detector to reduce scattered radiation.
X-ray absorption spectra for protein samples are recorded as the ratio F/I,
where F is fluorescence intensity and I is incident intensity. EXAFS spectra are
measured with 50 eV steps below the edge (9500-9630 eV), 0.2 eV steps in the edge
range (9630-9700 eV), and 50 eV steps in the EXAFS range (9700-10400 eV).
Integration time for each data point varies from 1 s in the pre-edge range to 8 s in the
edge and EXAFS ranges for a total integration time o f approximately 45 min per
scan. Total exposure time for each protein sample is about 16 h. About 15-20 scans
are taken for each protein sample, and each scan contains data from 8-10 detector
channels. The total incident count rate on each detector is maintained at about
20,000 cps without dead time correction, and an amplifier shaping time o f 1 jis is
used in all measurements. The windowed count rate of Zn K<x fluorescence for each
protein sample is several hundred cps per channel.
The EXAFS is extracted from the raw X-ray absorption spectra and analyzed
to yield simulated EXAFS x ( k) using EXAFSPAK, a suite o f computer programs for
analysis o f X-ray absorption spectra (Cramer et al., 1978; Cramer & Hodgson, 1979;
Teo, 1981; Scott, 1985). First, all scans are individually plotted and examined to
confirm the absence o f artifacts. Any spectrum showing irregularities is omitted
from further data processing.

Second, the raw XAS are recalibrated using the

transmission spectrum of the Zn foil standard. Third, 15-20 raw XAS for each
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protein sample are averaged. Fourth, the average XAS is used as input for EXAFS
data reduction manipulation: (i) Pre-edge background is subtracted by first-order
polynomial fitting; (ii) Above-edge background is corrected by two-region cubic
spline fitting; (iii) Average XAS is normalized to one Zn per molecule and converted
from E space to k space according to

K — [2me(E-E0)/h2] l/2 = [0.262449(E-Eo)]1/2

(1)

where K is the photoelectron wave vector in A '1, me is electron mass in kg, E is
photon energy in eV, E0 is threshold energy chosen as the photon energy at
half-height o f the absorption jump, and b. is Planck's constant. The data are weighted
to k3 space to offset attenuation of the EXAFS signal with increasing photon energy;
and (iv) The resulting EXAFS are Fourier transformed from energy space to radial
distance space. The simulated EXAFS is calculated as

X( k )= £ { [NsAs( k:)Sc/( xRas2)]exp(-2 Kr2a as2)exp(-2Ras/>.)sin[2 kR ^ 3>as(K) ] }
(2 )

where %( k ) is EXAFS amplitude function, N s is the number o f scattering atoms
within a shell, As(k") is the curved-w ave back-scattering am plitude o f the
absorber-scatterer pair, Sc is the scaling factor that accounts for the effect o f intrinsic
processes and is specific to the absorber-scatterer pair, a as2 is the mean square
deviation o f the absorber-scatterer bond length Ras, Q>as(K) is the distance-dependent
phase shift, and X is the photoelectron mean free-path.
The EXAFS is fitted to three EXAFS phase and amplitude functions to obtain
protein structural information. The first analysis is based on McKale curved-wave
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single-scattering theory.

A fter the Fourier transform ation over the range o f

k = 2.5-13 A-1, a radial distance R-window o f 0.8-3. 2 A is applied to filter out the
multiple-scattering contributions.

The filtered Fourier transformed spectra are

back-transform ed to k space for single-scattering EXAFS curve fitting.

The

goodness o f fit is described by the F factor, which is the sum of squares o f the
differences between experimental and calculated curves.
In addition to the single-scattering term to determ ine nearest-neighbor
distances, m ultiple-scattering contributions are often im portant in quantitative
calculations o f EXAFS. Especially in cases where the Zn ligands are rigid ring
structures such as the imidazole ring of histidine or purine ring o f purine riboside and
1-deazaadenosine, multiple-scattering terms are required for a good fit o f the raw
EXAFS. The Cerius2 multiple-scattering calculation is based on an automated
implementation o f (i) the curved-wave multiple-scattering theory (Gurman et al.,
1984; Gurman et al., 1986; Rehr & Albers, 1990) or the small atom theory (Gurman,
1988), (ii) an efficient method for enumerating multiple-scattering paths, (iii) ab
initio amplitude functions As(x)exp(-2Ras/^) and phase functions Oas( k) (Mustre de
Leon et al., 1991; R ehr et al., 1991; Rehr et al., 1992), and (iv) multiple-scattering
Debye-Waller factors. The calculation has four steps: (i) The scattering potentials,
phase shifts, dipole matrix elements, and absolute energies are calculated; (ii) The
scattering paths for the metal cluster are enumerated; (iii) The effective scattering
amplitudes and other EXAFS parameters are calculated for each scattering path; and
(iv) The EXAFS parameters from one or more paths are combined to calculate a total
EXAFS.

The geom etry information used by C erius2 is taken from the crystal

structures o f w ild-type mouse adenosine deam inase com plexes with HDPR and
1-deazaadenosine (W ilson et al., 1988; W ilson et al., 1991; Wilson & Quiocho,
1993). The sum in eq 2 is taken over all scattering atoms in a 6 A shell. The curve
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fitting uses k3-weighted data over the 2.5-13 A-1 range with the scaling factor Sc
fixed at 0.9 and the coordination num ber Ns fixed at integer values.

The

m etal-ligand distances and the D ebye-W aller-like factors exp(-2fc2cyas2) are
adjustable parameters. A nonlinear least-square Marquardt algorithm routine is used
to minimize the difference between the calculated and observed EXAFS.

The

quality of the fit, the R-factor, is defined as

R = I n, i [(l/Ci)(lXexptI(Ki)-Xth(Ki)l)] x 100%

(3)

where N is the number of data points, Xexptl(Ki) is the experimental EXAFS, Xth(Ki)
is the calculated EXAFS, and a , is defined as

1/cjj = Kin/lN , j Kjn lxexpll(*j)l

(4)

where n is a number chosen so that Knx exPtl(K) has approximately constant amplitude
over the data range.

Results and Conclusion
Protein Purification and Assay.

Mutant human adenosine deaminases,

including Glu217Ala and His238Ala, were originally purified in a one-column
procedure by immunoaffinity chromatography (Bhaumik et al., 1993). To avoid
exposing the proteins to a denaturant we chose an alternative purification scheme.
Glu217Ala and His238Ala have about the same affinities for substrate and inhibitors
as wild-type enzyme (Zeng et al., 1996), so the mutant proteins are purified by ligand
affinity chromatography in a two-step procedure involving DEAE-Sephadex and
purine riboside-Sepharose columns. After the ion-exchange colum n, the mutant
proteins are retarded on the purine riboside affinity colum n and are eluted
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Table 3.1. Purification of Glu217Ala and His238Ala mutant human adenosine deaminases from recombinant
baculovirus-infected insect larvae.

of the copyright owner. Further reproduction

total protein
mutant

fraction

volume (mL) enzyme units

(mg)

specific activity

(units)

(units/mg)

Glu217Ala

prohibited without perm ission.

crude extract supernatant

389

82

6.2

0.0159

DEAE eluate

106

425

ND"

ND

PR-Sepharose eluate

11.1

1

0.25

0.02

crude extract supernatant

280

80

4.7

0.02

80

400

ND

ND

4.08

1

0.52

0.13

His238Ala

DEAE eluate
PR-Sepharose eluate
"Not determined.

0\

00
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isocratically. A sample scheme is shown in Table 3.1. The prep is scaled to about
25 g o f larvae, which yield 6-11 mg o f GIu217Ala and 3-9 mg o f His238Ala. Yields
o f wild-type human adenosine deaminase are 4-10 mg purified by purine riboside
affinity chrom atography and 17-32 mg enzyme purified by adenosine affinity
chromatography. Glu217Ala and His238Ala mutants show a single band of >95%
purity on SDS-polyacrylamide gel electrophoresis. The specific activities o f the
mutant proteins purified by purine riboside chromatography agree with the values
obtained by immunoaffinity chromatography (0.02 for Glu217Ala and 0.13 for
His238Ala). The larvae have an endogenous deaminating activity that does not bind
to the immunoaffinity column (Bhaumik et al., 1993). The finding o f the same low
specific activities for the mutant proteins purified by the two methods suggests that
the larvae adenosine deaminase does not copurify w ith the recombinant mutant
enzymes on the purine riboside column.
W ild-Tvpe Hum an Adenosine Deaminase.

The fluorescence-detected

background-corrected Zn K-edge X-ray absorption spectra for free enzyme, HDPR,
and l-deazaadenosine com plexes o f wild-type human adenosine deaminase are
depicted in Figure 3.1. The relative height of the two peaks located at energies 9.716
and 9.742 Kev on the edge o f the XAS varies substantially among the three enzyme
forms. Since the near edge region is sensitive to the coordination geometry of the
Zn, the differences suggest that structural changes occur at the active-site Zn of
wild-type adenosine deaminase upon binding of ground- and transition-state analog
inhibitors.
The fc3-w eighted EXAFS x (x ) o f the w ild-type adenosine deaminase
complexes with transition-state analog inhibitor HDPR and ground-state analog
inhibitor 1-deazaadenosine are shown in Figures 3.2a and 3.3a. The Zn EXAFS of
different forms of adenosine deaminase is relatively strong without a clear beat
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Figure 3.1. The Zn K-edge X-ray absorption spectra of wild-type human adenosine deaminase for (O) free enzyme, ( + )
complexed with ground-state analog inhibitor 1-deazaadenosine, and (A) complexed with transition-state analog inhibitor
HDPR.
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Figure 3.2. Experimental (— ) and fit (••••) (a) EXAFS; (b) Fourier transform of
wild-type human adenosine deaminase com plexed with transition-state analog
inhibitor HDPR.
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Figure 3.3. Experimental (— ) and fit ( - • ) (a) EXAFS; (b) Fourier transform of
wild-type human adenosine deaminase complexed with ground-state analog inhibitor
1-deazaadenosine.
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pattern. The Fourier transforms o f EXAFS from 2.5-13 A '1 in fc-space are shown in
Figures 3.2b and 3.3b for HDPR and 1-deazaadenosine complexes, respectively.
Again, both the EXAFS raw data and their Fourier transforms show sizable changes
between different enzyme forms. The Fourier transform is dominated by a single
well-resolved peak centered at about 1.8 A with a few minor peaks above the noise
between 2 and 4 A. The dominant feature can be simulated by three Zn-N/O
interactions, but two additional Zn-N/O interactions near 2.3 and 1.8-2.1 A are
necessary in order to get a good fit (Table 3.2). The EXAFS and Fourier transform
patterns o f wild-type adenosine deaminase are similar to those observed in EXAFS
studies of Zn carboxypeptidase A, which has five Zn-N/O coordination (Zhang et al.,
1992; Zhang & Auld, 1993).
The EXAFS data were fit assuming four or five ligands coordinated to Zn.
When the EXAFS is analyzed with McKale curved-wave single-scattering theory,
distinctly better fits are obtained for the inhibitor complexes with a five-coordinate
N/O shell (F factor < 35) than with a four-coordinate N/O shell (F factor > 90). The
small features present beyond the central 1.8 A peak are probably due to
multiple-scattering interactions from the three imidazole groups o f His 15, His 17, and
His214 with some contributions from oxygens and carbons o f Glu217, His238,
Asp295, Asp296, G ly l84, and the bound inhibitors within 6 A o f the Zn. The
analyses o f these EXAFS data are greatly improved by using the multiple-scattering
formalism with Cerius2 (data not shown). The 6-hydroxyl group in HDPR complex
and the activated water/hydroxide in 1-deazaadenosine complex are omitted in the
four-coordinate multiple-scattering fits.
The crystal structure models o f ground- and transition-state analog inhibitor
complexes o f m ouse adenosine deaminase do not fit the profile o f EXAFS
experimental results o f the corresponding complexes o f human enzyme (Figure 3.4).
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Figure 3.4. Experimental EXAFS o f wild-type human adenosine deaminase and
calculated EXAFS from X-ray coordinates o f mouse adenosine deaminase (a)
complexed with ground-state analog inhibitor 1-deazaadenosine; (b) complexed with
transition-state analog inhibitor HDPR.
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There are two possible explanations for the discrepancy. First, there are subtle
differences in the environment o f the active-site Zn in mouse and human enzyme.
Second, the apparent differences in Zn-ligand distances are within the experimental
error o f the two techniques. The root-mean-square error in interatomic distances of
these complexes from X-ray diffraction is 0.2-0.3 A (W ilson et al., 1991), whereas
EXAFS error may be as small as 0.02 A. Therefore, EXAFS analysis considering
multiple-scattering most likely presents an accurate picture o f the active-site Zn
environment for adenosine deaminase.
For the human adenosine deaminase complex with transition-state analog
inhibitor HDPR, two of the Zn-N distances determ ined by EXAFS are identical
within error to the X-ray diffraction distances for the mouse enzyme complex and the
o

other three Zn-ligand distances are 0.1-0.2 A shorter (Table 3.2). There are five N/O
ligands coordinated to active-site Zn. The four-coordinate fit o f EXAFS gives an
unacceptable F factor o f 96.4 compared to 26.9 for the five-coordinate fit. The
five-coordination o f Zn confirms the hydration o f the inhibitor purine riboside to
H D PR in the enzym e-inhibitor complex observed by 13C-N M R and X-ray
diffraction (Kurz & Frieden, 1987; Wilson et al., 1991). However, the Z n -0 distance
to 0 6 o f HDPR is only 2.06 ± 0.02 A, significantly shorter than the X-ray value of
2.29 A. These results provide strong support for the coordination environment of the
active-site Zn in the transition-state analog inhibitor complex determined by X-ray
crystallography though give slightly different values for three o f the Zn-ligand
distances.
For the human adenosine deaminase com plex w ith ground-state analog
inhibitor 1-deazaadenosine, the EXAFS results also offer strong support for the
five-coordination environment of the active-site Zn found by X-ray crystallography
for the mouse adenosine deaminase complex.

Four o f five EXAFS Zn-ligand
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Table 3.2. EXAFS results for wild-type human adenosine deaminase.
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Free ADA
R (o )

(A )

ADA/DAA Complex

ADA/PR Complex

R (a )(A )

R ca (A )

R ( a ) (A )

R ca (A )

prohibited without perm ission.

Zn-N

2.24 (0.03)

2.11 (0.04)

2.24

2.29 (0.06)

2.31

Zn-N

2.06 (0.02)

2.12(0.04)

2.03

2.14 (0.05)

2.16

Zn-N

2.07 (0.02)

2.00 (0.02)

1.59

2.14(0.05)

2.23

Z n-0

2.24 (0.03)

2.19(0.02)

2.27

2.27 (0.02)

2.40

Zn-O

1.73 (0.04)

1.82 (0.02)

1.80

2.06 (0.02)

2.29

F4c

123.3

102.1

ND*

96.4

ND

p 5r/

32.6

5.6

ND

26.9

ND

flZn-ligand distance from X-ray crystal structure of mouse adenosine deaminase. ^Not determined. cF-factor for fourcoordinate fits. ^F-factor for Five-coordinate fits.
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distances are within about 0.1 A o f the X-ray values. However, one Zn-N distance
p

from EXAFS is 0.4 A longer. Here too, the four-coordinate fit is rejected because of
poor F factor o f 102.1 compared to 5.6 for the five-coordinate fit. Five-coordination
o f the active-site Zn confirms the activated water or hydroxide proposed in the X-ray
crystal structure (W ilson & Quiocho, 1993). The Zn coordination sphere o f the
ground-state analog inhibitor complex is smaller than that o f the transition-state
analog inhibitor complex in both human and mouse wild-type adenosine deaminases.
EXAFS data show: (1) In the HDPR complex, two o f the His residues are 0.1-0.2 A
farther from Zn then they are in the deazaadenosine complex. (2) The Z n-0 distance
to Asp295 decreases from 2.27 ± 0.02 A in the HDPR complex to 2.19 ± 0.02 A in
the deazaadenosine complex. (3) The Z n-0 distance to 0 6 o f HDPR is 2.06 ± 0.02
A com pared to the Zn-w ater/hydroxide distance o f 1.82 ± 0.02 A in the
deazaadenosine complex.
In the case o f free human adenosine deaminase, the corresponding crystal
structure for mouse enzyme is not available. Therefore, coordinates for the mouse
enzyme complexes with ground- and transition-state analog inhibitors were used as
starting geometries in EXAFS analyses. The atoms in the purine rings within 6 A
from Zn were removed for the multiple-scattering analyses. The four-coordinate fit
o f EXAFS o f free enzyme also gave a poorer fit with F factor o f 123.3 compared to
32.6 for a five-coordinate fit. This indicates that there are five coordination sphere
N/O ligands bound to active-site Zn and provides the first evidence o f an "activated
water" in free adenosine deaminase. Thus, it appears that the water is ordered or
activated and ready to attack the substrate prior to formation o f the Michaelis
complex. The activation o f the water molecule and tendency to form and localize the
hydroxide are favored by the alignment of Zn and some active-site amino acid
residues, such as His238 and Asp295 in free adenosine deaminase. Inspection o f the
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crystal structures o f the two mouse enzyme com plexes reveals three likely
interactions between the water molecule and active-site ligands in the free enzyme:
coordination of the water oxygen to the powerful Zn electrophile plus hydrogen
bonding o f one water hydrogen to 051 o f Asp295 and o f the other hydrogen to Ne2
of His238. The Z n-0 distance from "activated water" is shorter in free enzyme (1.73
± 0.04 A) than in ground-state analog inhibitor complex (1.82 ±

0 .0 2

A), suggesting

that the binding of ground-state substrate plays a role in the displacement o f the
"activated water" to form the hydroxyl in the transition state.
Structures o f the active sites o f enzymes are modified by the binding of
substrate or inhibitor, as was postulated by Koshland (1958) more than three decades
ago and reexamined by Post and Ray (1995) recently. These conformational changes
upon binding of substrate or inhibitor orient functional groups on the enzyme to
enhance efficiency of formation o f the transition state as well as subsequent chemical
processes. This type o f dynamic recognition is defined as induced fit. In the case of
adenosine deaminase, starting from free enzyme, the active-site Zn coordination
environm ent is close to that o f ground-state analog inhibitor complex.

This is

evident by comparing the EXAFS results o f free human adenosine deaminase and its
ground-state analog inhibitor complex. Five ligands are coordinated to active site Zn
with sim ilar Zn-ligand distances.

This tells us that the active site structure is

maintained upon binding of 1 -deazaadenosine, a ground-state analog inhibitor o f the
enzyme, and suggests that the active site o f adenosine deaminase is designed to fit
the ground state o f substrate.

In contrast, significant changes in active-site Zn

coordination environment occur after the enzyme binds purine riboside, which is
hydrated at C 6 immediately after binding and forms the near ideal transition-state
analog HDPR with a tetrahedral structure at C 6 . The induced fit in adenosine
deaminase in the transition state expands the coordination sphere o f Zn by about 0.1
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A, especially the Z n -0 distance to activated water/hydroxide or 0 6 o f HDPR (from
1.73 ± 0.04 in free enzyme to 2.06 ± 0.02 in HDPR complex), well beyond the error
in the EXAFS results. Since hydroxide is a better proton acceptor than hydroxyl, the
Zn-O H ' distance is generally about 0.2 A shorter than the Zn-OH distance in small
inorganic compounds (Kimura et al., 1990), in agreement with the EXAFS results.
His 15, H isl7 , H is214, and Asp295 open up and pull away from Zn, while the
water/hydroxide moves away from Zn and presumably closer to C 6 of the inhibitor
to form the transition state o f the substrate.

This increase in size o f the Zn

coordination sphere from ground-state to transition-state enzyme complex is also
apparent in the X-ray structures o f mouse adenosine deaminase com plexes with
ground- and transition-state analog inhibitors (W ilson et al., 1991; W ilson &
Quiocho, 1993).

Previously, fluorescence studies demonstrated that adenosine

deaminase undergoes different conformational changes upon binding o f ground- and
transition-state analog inhibitors (Kurz et al., 1985; Philips et al., 1987; Philips et al.,
1989).
Free Enzym es and Ground-State Analog Inhibitor Complexes o f Mutant
Human A denosine Deaminases. The biochem ical and biophysical properties of
Glu217Ala and His238Ala mutants were characterized previously (Bhaumik et al.,
1993; Zeng et al., 1996).

Substitution o f Glu217 or His238 by alanine causes

complete loss o f enzym e activity and 30 or 50% loss o f a -h e lic a l content,
respectively. However, both mutants retain normal substrate and inhibitor binding
affinity and P-sheet content.

Apart from the missing carboxylic acid group of

Glu217 or imidazole group o f His238, the enzyme active site inside the P-barrel
appears to be largely intact. The EXAFS data analysis of free and ground-state
analog inhibitor complexes of these two mutants improves significantly for fivecoordinate fits com pared to four-coordinate fits as shown in Tables 3.3 and 3.4.
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Table 3.3. EXAFS results for Glu217Ala mutant human adenosine deaminase.
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Free ADA

ADA/DAA Complex

ADA/PR Complex

R (a) (A)

R (a) (A)

R(a)(A)

Zn-N

2.29 (0.05)

2 . 1 2 (0 .0 2 )

2.29 (0.05)

Zn-N

2.08 (0.03)

2 . 1 2 (0 .0 2 )

2.20 (0.05)

Zn-N

2.08 (0.03)

2.03 (0.04)

2.05 (0.02)

Zn-O

2.25 (0.03)

2.23 (0.07 )

2.17 (0.04)

Z n-0

1 .6 8

(0.06)

1.79 (0.02)

1.69 (0.06)

prohibited without perm ission.

f 4«

98.7

111.7

106.4

f 5*

18.1

7.3

24.3

°F-factor of four-coordinate Fits. ftF-factor of five-coordinate fits.

oo
O
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EXAFS of free and ground-state analog inhibitor complexes o f GIu217Ala
and His238Ala mutants gives the following results: (1) The Zn-ligand distances of
the two free mutant enzymes are almost identical to those o f free wild-type enzyme,
with a root-mean-square deviation o f

0 .0 1

A for both mutants. This confirms that

the structure o f the active site o f Glu217Ala and His238Ala mutants is not perturbed
by the amino acid replacement (Zeng et al., 1996); (2) There is also remarkable
similarity among the three ground-state analog inhibitor complexes of wild-type,
Glu217Ala, and His238Ala adenosine deaminases; and (3) The Zn-ligand distances
in the active site of free enzyme are similar to those o f deazaadenosine complex for
both Glu217Ala and His238Ala mutants, with root-mean-square deviations of 0.04
and 0.03 A for G lu217A la and His238AIa, respectively.

The mutant results

strengthen the conclusion that there is little conformational change in the active site
of adenosine deaminase upon binding of ground-state inhibitor.
Transition-State Analog Inhibitor Complexes o f M utant Human Adenosine
D e am in a ses.

The EXAFS data analysis o f transition-state analog inhibitor

complexes of these two mutants also indicates Five-coordination o f the active-site Zn
(Tables 3.3 and 3.4). Unlike the free enzymes and ground-state analog inhibitor
complexes, the complexes o f the mutants with the transition-state analog inhibitor
purine riboside have different active site geometries. For Glu217Ala mutant, the
Zn-ligand distances are almost identical in the free enzym e and purine riboside
complex apart from one Zn-N distance. The purine riboside complex o f Glu217Ala
mutant differs from the HDPR complex o f wild-type enzyme. Especially the Zn-O
distance to 0 6 on HDPR in wild-type enzyme complex o f 2.06 ± 0.02 A is replaced
in the mutant complex by a much shorter Zn-0 distance o f 1.69 ± 0.06 A. This short
Z n -0 distance in the purine riboside complex o f G lu217A la is identical to the
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Table 3.4. EXAFS results for His238Ala mutant human adenosine deaminase.

Free ADA

ADA/DAA Complex

ADA/PR Complex

R (a) (A)

R « t)(A)

R (a) (A)

Zn-N

2.26 (0.04)

2.18(0.02)

2.31 (0.06)

Zn-N

2.04 (0.03)

2.13(0.05)

2.15 (0.05)

Zn-N

2.09 (0.04)

2 .0 0

(0 .0 2 )

2.14(0.05)

Z n-0

2.25 (0.03)

2.29 (0.02)

2.26 (0 .0 2 )

Zn-O

1 .6 8

(0.06)

1.69(0.04)

2.07 (0.02)

prohibited without perm ission.

F4°

97.7

136.8

111.9

f 5*

22.3

23.8

25.4

aF-factor of four-coordinate fits.

6 F-factor

of five-coordinate fits.

00

to
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1 .6 8

± 0.06 A Zn-O distance in the free enzyme. It is too short to be a Zn-hydroxyl

distance and likely represents a Z n -0 distance from activated water/hydroxide,
consistent with formation o f a ground-state complex. However, the Z n-0 distance in
purine riboside complex is about

0 .1

A shorter than the corresponding distance in the

ground-state analog inhibitor complex with

1 -deazaadenosine,

perhaps due to the

presence of the amino group of adenosine.
The above conclusion from EXAFS agrees with results from previous studies
of Glu217 mutants of mouse adenosine deaminase by solvent difference UV and
13 C-NMR

spectroscopies (Mohamedali et al., 1996). In the proposed catalytic

m echanism o f adenosine deam inase based on X -ray diffraction studies o f
ground- and transition-state analog inhibitor complexes of mouse enzyme, Glu217 is
an active-site amino acid residue (Wilson et al., 1991; W ilson & Quiocho, 1993).
The carboxylic acid group of Glu217 protonates the purine ring. In Glu217Ala
mutant, Ala obviously is unable to carry out the function o f Glu without the
carboxylic acid group. A more conservative substitution, such as Glu217Asp, should
retain the ability to form the tetrahedral transition state, thus preserving more
catalytic activity. The mouse Glu217Asp mutant has 20-fold higher specific activity
than the human G lu217A la mutant (mouse and hum an wild-type adenosine
deaminases have the same specific activity; Mohamedali et al., 1996).
For the purine riboside complex of His238Ala mutant, the EXAFS results are
sim ilar to the H D PR com plex o f wild-type enzym e.

The Z n -0 distance o f

His238Ala purine riboside complex increases alm ost 0.4 A compared to the free
mutant enzyme and ground-state analog inhibitor complex. The mutant complex has
almost identical Zn-ligand distances as the HDPR complex o f wild-type enzyme.
This is strong evidence for formation of the transition state in the purine riboside
complex of His238Ala. In the most recent mechanism o f adenosine deaminase,
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His238 is proposed to play two roles in catalysis (Wilson & Quiocho, 1993). In the
first step, it acts as a general base in abstracting a proton from the activated water
and stablizing the pre-transition state. After formation o f the transition state, the
abstracted proton on Ne2 of His238 acts as a proton donor to the N 6 amino leaving
group o f substrate. Our EXAFS results show five cordination o f the Zn for wild-type
and mutant enzymes in the absence and presence of inhibitors, suggesting that there
is always an activated water molecule or hydroxyl ligand on the Zn. The activation
o f the water molecule is facilitated by coordination of water oxygen to the powerful
Zn electrophile and donation o f one hydrogen to a hydrogen bond with 0 5 1 of
Asp295.

Therefore, it is not surprising that the water is able to act as a weak

nucleophile attacking C 6 of substrate to form a tetrahedral transition state without
help from His238 when all the other important active-site ligands, such as Asp295
and Zn, are present. Nevertheless, the catalytic activity o f His238AIa has dropped
3000-fold com pared to w ild-type, though kcat is about 5 tim es higher than
Glu217Ala (Bhaumik et al., 1993; Zeng et al., 1996). W hat makes the His238 so
essential after the successful formation o f the transition state? It seems to be related
to the second role o f His238 in catalysis. W ithout the imidazole group o f His238
proton donation to the N6 amino group cannot occur, which obviously hinders the
deamination.
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APPENDIX

A. Construction of Recombinant Baculovirus for Wild-Type Human Adenosine
Deaminase (Medin et al., 1990)
Human adenosine deaminase cDNA , the £coR I-£coR I fragment of a human
adenosine deaminase clone (from a lambda phage gtlO library), is first inserted into
the Eco RI site o f pBR322 to generate plasmid pBR 8 . pBR 8 is digested with H inf I,
filled in with DNA polymerase Klenow fragment, and then digested with Nco I.
This Nco I-blunt fragment is isolated from a low-melting temperature agarose gel
and ligated into the pAcC4 baculoviral transfer vector DNA that has been prepared
as illustrated in Figure A. 1. The vector DNA is digested with Bam HI, extended at
the restriction site with the Klenow fragment, and then digested with Nco I to create
a directed cloning site.

The resulting construct is term ed pAcC4ADA and is

designed to encode a nonfusion protein after hom ologous recom bination with
AcMNPV, the insect baculovirus as illustrated in Figure A .2.

AcMNPV

(baculovirus DNA) is purified (Summers & Smith, 1987), and 1 (ig o f purified
extracellular virus DNA is combined with 2 jig o f C sC l-purified pAcC4ADA
transfer virus constructs in a cotransfection of Sf9 cells (Summers & Smith, 1987).
Recombinant viruses that have undergone homologous recombination (designated
AcMNPV) are identified by visual screening o f plaque isolates in a plaque assay,
facilitated by the uptake o f neutral red dye into uninfected viable cells (Brown &
Faulkner, 1977; Summers & Smith, 1987). Putative recombinant viral isolates are
identified as nonstained cells containing no polyhedrin protein occlusion bodies.
Recombinant viruses are isolated and plaque-purified two o r three times to obtain
pure recombinant virus stocks. Blot hybridization and polymerase chain reaction are
used to identify the recombinant virus.
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Figure A.2. Synthesis of the pAcC4ADA baculoviral transfer vector and the recombinant virus AcMNPV adenosine deaminase.

Insect larvae are produced by hatching Trichoplusia n i eggs. Larvae (Fourth
instar) are sedated by incubation on ice for 15 min and then injected near the proleg
with 10 mL o f m edium containing recombinant baculovirus.

When optimum

quantities of recombinant enzyme accumulated in the insects (4 days after injection),
larvae are harvested and immediately frozen at -70 °C.
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B. Construction of Recombinant Baculovirus for Mutants of Human Adenosine
Deaminase (Sambrook et al., 1989)
Construction of Vector M13nADA for Mutagenesis
The adenosine deaminase cDNA is cloned into vector M13nADA to facilitate
the site-specific mutagenesis o f selected regions. This construct is made as follows
(Figure B .l). The adenosine deaminase cDNA is released from vector pB R 8 as
described in Appendix A with the restriction enzyme H in f I. Phosphorylated linker
oligos (5'-A G TCCA TG G -3') that convert the H in f I site to an N co I site are
self-annealed and then added as duplexes (The phosphorylated linker oligos are in a
50-fold molar excess compared to the cDNA of adenosine deaminase) and ligated to
the H in f I ends obtained from the digestion. After a re-digestion with restriction
enzyme Nco I, the cDNA with Nco I ends is subcloned into the baculoviral transfer
vector at the N co I site as a shuttle intermediate. This vector is then identified as
pAcC4ADA' to distinguish it from the vector pAcC4ADA used in the baculoviral
expression. Large amount o f pAcC4ADA' are isolated and the plasm id is then
digested w ith the restriction enzyme N co I.

After a phenol extraction step,

phosphorylated N co I to Eco RI linker duplexes (self-annealed) are added (The
sequence o f the oligo is 5'-CATGGGAATTCC-3'.).

The resulting ligation is

digested w ith restriction enzyme E c o RI and the 1.1 kb band eluted onto
nitrocellulose and extracted into TE buffer. The isolated adenosine deam inase
cDNA is then ligated into dephosphorylated vector M 13m pl8 at the Eco RI site and
used to transfect frozen competent D H 5 a F cells. The orientation of the cDNA in
the resulting vector M13nADA is then determined by restriction enzyme analysis.

Construction of Single-Site Mutations
V ector M 13nADA is used in the construction o f all site-specific mutant
forms of human adenosine deaminase. Single-stranded DNA containing uracil is
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Figure B .l. The Construction lineage o f vector M 13nADA and mechanism of the
single-Site mutagenesis of human adenosine deaminase.
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made as described in the Bio-Rad Muta-Gene M13 in vitro mutagenesis kit (Bio-Rad
labs, Richmond, CA).
Uracil-containing M13nADA is produced from strain BD2399 grown with
the addition o f tetracycline and uridine. The cells are grown to an ODgoo o f 0.1.
M13nADA phage is added at the recommended low multiplicity of infection (MOI).
The cells and phage are grown at 37 °C for 5 hr with vigorous shaking and
then the uracil-containing phage are recovered as follows. The E. coli cells are
pelleted by repeated centrifugation at 17,000 x g for 15 min in an SS-34 rotor
(Sorvall) using polyallomer tubes. RNase is then added to the supernatant and the
reaction incubated for 15 min at room temperature. To this reaction a solution of
20% PEG-8000 containing 2.5 M NaCl is then added and the resulting product is
incubated on ice for 30 min.

The uracil-containing phage is recovered by

centrifuging the above product at 17,000 x g for 20 min at 4 °C. The supernatant
produced in this step is completely removed and the pellet resuspended in a high salt
buffer (300 mM NaCl/100 mM Tris, pH 8/1 mM EDTA) and stored on ice for 30
min. This stock solution is then extracted with phenol and phenol/chloroform /
iso-amyl alcohol directed in Muta-Gene kit. The purified single-stranded (containing
uracil) M 13nADA DNA is then subjected to analysis on a 1% TBE-agarose gel and
quantitated by an A 2 6 0 /A 2 8 Omeasurement.
Site-specific mutagenesis is performed as in the M uta-Gene kit protocol.
Single-stranded uracil containing M 13nADA is combined with phosphorylated
mutagenic oligomers and annealing buffer (20 mM Tris-Cl, pH 7.4/2 mM MgCl2/50
mM NaCl) and heated to 80 °C for 5 min. The reaction then is allowed to cool
slowly to room temperature over 30 min and stored on ice. The second-strand
synthesis reaction on the template and primer annealed product is accomplished by
the addition o f Sequenase v.II, DNA synthesis buffer (0.4 mM each dNTP/0.75 mM
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ATP/17.5 mM Tris-Cl, pH 7.4/3.75 mM MgCl2 /21.5 mM DTT), and T4 DNA ligase.
The reaction is incubated on ice for 5 min, incubated at room temperature for 5 min,
and then heated to 37 °C for 90+ min. The DNA sam ple is electrophoresed on a
0.8% TBE-agarose gel, and stained with EtBr to observe the shift in the molecular
weight of the DNA bands upon second-strand synthesis.

A significant shift to

supercoiled and nicked circle forms is observed in the reactions including primers in
contest to the lane where no primer is added. The reaction product, containing the
newly synthesized second strand (without uracil residuals) is then used to transfect
frozen competent DH5ocF cells. The isolates containing the mutations are screened
by restriction analysis and sequenced to confirm the identity o f the mutation and to
insure the fidelity of the surrounding nucleotides.
The mutated cDNAs in vector M13nADA are recloned into the baculoviral
transfer vector pA cC 4 at the N co I site and expression analysis in the
baculovims/Trichoplusia ni system is performed. Recombinant viruses are identified
by PCR analysis and altered protein is made in each case. Expression and activity
levels are analyzed in Sf9 cells and injected larvae as described in Appendix A.
The purification o f recombinant mutants o f human adenosine deaminase from
injected larvae is accomplished using a monoclonal antibody column (Philips et al.,
1987), or a DEAE/purine riboside-Sepharose tw o-colum n process (Zeng et al.,
1996).
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C. EXAFSPAK: a Suite o f Computer Programs for Analysis of X-Ray
Absorption Spectra
The EXAFS is extracted from the raw X-ray absorption spectra data and
analyzed to yield simulated EXAFS %(k) using EXAFSPAK, a suite o f computer
programs for analysis of X-ray absorption spectra (documentation by Graham N.
George, and Ingrid J. Pickering) (Cram er et al., 1978; Cramer & Hodgson, 1979;
Teo, 1981; Scott, 1985).

MVIEW
The program MVIEW is used to plot data from X-ray absorption spectra. In
X-ray absorption spectra collection, each individual XAS spectrum contains 8-10
scans from different detector channels. All the scans are individually plotted and
examined to confirm the absence of artifacts, and any scan showing irregularities is
omitted for the further data processing.

MCALIB
The program MCALIB is used to re-calibrate data by reading a standard
from a raw X-ray absorption spectrum file, which, in the case o f hum an adenosine
deaminase, is the transmission spectrum o f Zn foil standard.

The results are

displayed on the terminal screen and written to an ASCII file Calibrate.Dat. The
program searches for peaks in the derivative and uses a quartic polynomial fitted to
the data, combined with a Newton Raphson search algorithm to accurately find peak
positions.

MDEAD
The program MDEAD determines detector dead times from experimentally
measured dead time curves and is designed for use with multi-element solid-state
array detectors such as C anberra

1 elem ent ultrapure germ anium array.

Experimentally these measurements are made by scanning a slit blade through the
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incident X-ray beam while monitoring the output o f all the detectors. All photon
counting detectors suffer from electronic dead time to some degree. The electronic
dead time is primarily associated with the shaping amplifier. The correction method
o f electronic dead time depends on the collection o f a total incoming count rate
signal from the shaping amplifier. This signal does not suffer from the same dead
time effects as the shaped pulses, which are normally fed to a signal channel
analyzer.

The correction applied by MDEAD is for the type of extending or

paralyzing dead-time, which is described as,

y=Kpe-PT

(1)

where t is the dead-time, y is the SCA, p is the ICR, and k is a constant of
proportionality. MEAD reads a raw XAS data file containing a dead-time curve,
determines the values of k, p, and x, so as to determine electronic dead-times and
write the output file Deadtim e.Dat.

The .Dat files from MDEAD are used by

MAVE.

MAVE
The 15-20 individual raw XAS spectra of each protein sample are computed
to one output averaged data file (.AYE file) with MAVE program. MAVE is used
for averaging raw XAS data files with electronic dead-time correction using the
inform ation in D eadtim e.D at if needed.

In addition to catering for simple

transmittance spectra, MAVE is designed to convert data from multielement solid
state detector arrays and therefore can perform energy calibration of the XAS data,
and selective statistical weighting o f individual data file array positions (channels)
from array elements. The .AVE file generated from MAVE program is used by
PROCESS and OPT programs for further data analyses.
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PROCESS
The .AVE file is used as an input file for program PROCESS for EXAFS
data reduction manipulation: (i) pre-edge background subtraction by first-order
polynomial fitting; (ii) above-edge background correction by two-region cubic spline
fitting; (iii) normalization; (iv) data (a function of energy E) conversion to a function
o f k according to

k = [2me(E-Eo)/h2] I/2 = [0.262449(E -E o)]1/2

(2)

where k is photoelectron wave vector and has a unit of A '1, me is electron mass, E is
the photon energy, Eo (threshold energy) is the X-ray absorption edge energy and
chosen as the photon energy at half-height o f the absorption jum p, and h is the
Planck's constant. The data are weighed to k 3 space to offset attenuation o f the
EXAFS signal with increasing photon energy; and (v) the resulting EXAFS data are
Fourier transformed from energy space to radial distance space and different regions
of the transform are back-transformed to yield Fourier-filtered spectra.(saved as .FIL
files). The processed XAS data are re-written to either new .AVE files or Fourierfiltered .FIL files. Finally, the processed .AVE and .FIL files are used as the input
files for OPT program. OPT is the EXAFS curve fitting analysis program and can
use a variety of EXAFS phase and amplitude functions to obtain protein structural
information. The simulated EXAFS is calculated as

X(k) = I { [ N sA s(k)Sc/kRas2]exp(-2K2aas2)exp(-2Ras/X)

sin[2kRas + 4>as(K)]}

(3)

where x(k) is EXAFS amplitude function, Ns is the number o f scattering atoms
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within a shell, A s(k ) is the curved-w ave back-scattering am plitude o f the
absorber-scatterer pair, Sc is the scaling factor that accounts for the effect o f intrinsic
processes and is specific to the absorber-scatterer pair, <7 a s 2 is the mean square
deviation o f the absorber-scatterer bond length Ras, O ^ k ) is the distance-dependent
phase shift, and X is the photoelectron mean free-path.

OPT
OPT is the EXAFS curve fitting analysis program which is used to obtain
structural information. It reads .AVE or .FIL files from PROCESS and can use a
variety o f different phase and amplitude functions.

These functions are the

following: McKale curved wave theory, using 1/R interpolation to the initial value
of distance; parameterized phase and amplitudes; Fourier filter extracted phase and
amplitude functions from PROCESS; FEFF curved wave single scattering theory;
FEFF curved wave multiple scattering theory; EXAFSPAK FEFF tables; and ASCII
file input, phase and amplitude from some external source. The goodness o f a fit is
evaluated by F-factors, which are the sum o f the squares of the differences between
experimental and calculated EXAFS curves.
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D. Abbreviations
A

adenosine

AcMNPV

autographa califomica nuclear polyhedrosis virus

ADA

adenosine deaminase

2-APr

2-aminopurine riboside

ATP

adenosine triphosphate

CCA

convex constraint algorithm

CD

circular dichroism

cps

counts per second

DAA

1-deazaadenosine

dNTP

deoxy-N triphosphate (N = adenosine, guanosine, thymidine, or
cytidine)

EPR

electron paramagnetic resonance

EtBr

ethidium bromide

EXAFS

extended X-ray absorption fine structure

GdmCl

guanidinium chloride

HDPR

6 (R)-hydroxy-dihydropurine

I

inosine

ICR

incoming count rate

Kb

kilo base pair

MOI

multiplicity o f infection

NSLS

National Synchrotron Light Source

PCR

polymerase chain reaction

PR

purine riboside

SCA

signal channel analyzer

riboside
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SCID

severe combined immunodeficiency disease

SSRL

Stanford Synchrotron Radiation Laboratory

Sf9

Spodoptera frugiperda

XAS

X-ray absorption spectroscopy
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F. Epilogue
At the time when this dissertation was defended, EXAFS data were analyzed
with a single-scattering method as described in chapter 3. However, an improved
data analysis was done recently with a multiple-scattering method using the Cerius2
program.

The new results confirm ed the existence o f the five-coordination

environment for the active-site Zn o f human adenosine deaminase, but were unable
to distinguish the Zn-ligand distance differences among the free enzyme, and
ground- and transition-state analog inhibitor complexes o f wild-type and mutant
adenosine deaminases. Detailed results will be presented in the following paper
entitled "Zn-Binding Ligands at the Active Site o f Human Adenosine Deaminase: an
EXAFS Investigation," Qing Zeng, Karen Gathy, Mary Sue Coleman, and Mary D.
B arkley, w hich is currently in preparation for subm ission to the journal
Biochemistry.
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